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ABSTRACT 
Aims 
 
The objective of study I was to evaluate the role of serum cystatin C in elderly cardiac 
surgery patients and study II in heart transplant patients, and to test if serum cystatin C can 
detect postoperative acute kidney injury (AKI) earlier than plasma creatinine after cardiac 
surgery. In study II the aim was to discover if urine N-acetyl-β-glucosaminidase (U-NAG) 
is able to uncover kidney injury in heart transplant patients immediately after surgery. N-
acetylcysteine (NAC) and levosimendan were investigated for the protection of kidneys in 
studies III and IV, respectively. 
 
 
Material and methods 
 
Study I included 110 cardiac surgery patients aged 70 or more. Serum cystatin C and 
plasma creatinine samples were collected before surgery for the baseline values and on 
postoperative days 1 to 5. Urine output was registered and estimated glomerular filtration 
rate (eGFR) calculated. AKI was determined by using the risk-injury-failure-loss-end 
stage (RIFLE) criteria and correlation of plasma creatinine and serum cystatin C with AKI 
was calculated. 
Study II included 41 heart transplant patients. Plasma creatinine and serum cystatin C 
samples were collected preoperatively and postoperatively on days 1 to 5, and U NAG and 
creatinine samples preoperatively, at the end of surgery, and on postoperative days 1 to 5. 
AKI patients were defined according to RIFLE classification. 
Study III included 80 patients with preoperative renal dysfunction undergoing cardiac 
surgery. The patients were randomized to receive in double-blind manner intravenous N-
acetylcysteine (n=38) or placebo (n=39) at the induction of anesthesia, followed by 20 
hour infusion. Kidney injury was defined as increase of plasma creatinine more than 44 
μmol/l or more than 25% from the baseline. Kidney function was determined with plasma 
creatinine, serum cystatin C, and the ratio of urine creatinine and NAG. 
Study IV was a study of 60 patients with left ventricular ejection fraction ≤ 50%. In 
this randomized, double blind study patients received an infusion of levosimendan or 
placebo starting after induction of anesthesia and continuing for 24 hours. In both studies 
kidney injury was determined with U-NAG and renal function was measured with plasma 
creatinine and serum cystatin C. AKI was defined using RIFLE criteria. 
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Main results 
 
AKI occurred in 56 % of the patients in study I. There was no significant difference in the 
correlation of cystatin C and creatinine with AKI at different time points.   On the first 
postoperative day the area under the curve (AUC) for cystatin C was 0.71 (0.61- 0.76) and 
for creatinine 0.66 (0.55-0.76), Δ AUC 0.05 (0.01 - 0.12), p = 0.11. On the second 
postoperative day AUC for cystatin C was 0.77 (0.68-0.86) and for creatinine 0.74 (0.64-
0.83), Δ AUC -0.03 (-0.09-0.03), p = 0.32. Both markers peaked on the third day after 
surgery. 
In study II 56% of patients developed postoperative AKI according the RIFLE criteria, 
and 31% of the patients with AKI required renal replacement therapy (RTT). There was 
no significant difference between the changes of plasma creatinine and cystatin C over 
time with AKI patients, but in patients without AKI, serum cystatin C increased 
significantly more than plasma creatinine. U-NAG increased in all study patients after 
surgery indicating some changes in tubular function. However, there were no significant 
difference between patients with AKI and patients without AKI.  
In study III there was no significant difference between the NAC-group and placebo-
group in concentrations of plasma creatinine, serum cystatin C and urine NAG and 
creatinine ratio. AKI occurred in 45% of all study patients. 
In study IV there was no significant difference in renal function between the patients 
treated with levosimendan or placebo. In the placebo group 13 out of 30 patients 
developed AKI. In levosimendan group 8 out of 30 patients had AKI, p = 0.167. 
 
 
Conclusions 
 
In cardiac and heart transplant surgery patients serum cystatin C detects AKI equally as 
compared plasma creatinine. Pharmacological treatments with N-acetylcysteine or 
levosimendan did not prevent the development of postoperative AKI after cardiac surgery. 
 
 
Keywords 
 
Cardiac surgery, acute kidney injury, heart transplantation, cystatin C, N-acetylcysteine, 
levosimendan 
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1. INTRODUCTION 
Cardiac surgery associated acute kidney injury (CSA-AKI) manifests as rapid decline in 
glomerular filtration rate (GFR) after cardiac surgery.  In a multicenter study it was the 
second most common cause of AKI after sepsis in the intensive care unit (ICU).1 CSA-
AKI has been associated independently with increased mortality, morbidity, and hospital 
costs. Even a small increase in serum creatinine after cardiac surgery was associated 
nearly three-fold increase in 30-day mortality, and in severe AKI requiring RRT mortality 
increased up to 63%.2,3 
 
The reported incidence of CSA-AKI has varied depending on the definition of AKI. 
During last decade a consensus of the criteria of AKI has been established. Based on acute 
changes in serum creatinine, GFR, and urine output, Acute Dialysis Quality Initiative 
(ADQI) proposed The Risk, Injury, Failure, Loss of function, End-stage kidney disease 
(RIFLE) criteria.4 Acute Kidney Injury Network (AKIN) modified it in 2007 and Kidney 
Disease: Improving Global Outcomes (KDIGO) in 2012.5,6 Based on RIFLE or AKIN 
criteria the range of CSA-AKI incidence is between 9 and 39%.2,7-10 
The etiology of CSA-AKI is complex including exogenous and endogenous toxins, 
metabolic abnormalities, ischemia and reperfusion injury, neurohormonal activation, 
inflammation, and oxidative stress.11 These factors overlap and recur during the 
perioperative period making it more difficult to target renoprotective treatments. Several 
patient-related risk factors have been identified, of which the most important may be 
preoperative kidney injury and dysfunction. Furthermore the severity of perioperative 
cardiac dysfunction may have consequential impact on the development of postoperative 
AKI.12 
 
In cardiac surgery the dilutive effect of cardiopulmonary bypass (CPB) pump prime 
fluid may postpone the detection of decreased kidney function when using conventional 
measurement by serum creatinine. Therefore the novel kidney function biomarker cystatin 
C has been tested to find out if it can detect postoperative AKI earlier than creatinine, but 
the results have been inconclusive.13 Also, other novel biomarkers as of kidney damage 
have been diligently studied to help further refine existing criteria of AKI. Although these 
biomarkers are not yet in wide clinical use, ADQI consensus conference proposed that 
some of these markers may be used to diagnose AKI in appropriate clinical settings.14 
 
Today, more complex cardiac surgery is performed in older patients who have more 
co-morbidities predisposing them to the development of CSA-AKI. Although the 
understanding of the pathophysiology of AKI has increased, considerable progress has 
been made in more accurate definition of AKI, and more sensitive kidney damage 
biomarkers have emerged, there has been very little progress in the detection, prevention, 
and management of SCA-AKI.15 No pharmacologic interventions have demonstrated clear 
efficacy in prevention of CSA-AKI.16 Some therapies may offer protection against AKI, 
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such as mitigating preoperative anemia, avoiding perioperative red blood cell transfusions, 
and trying to prevent surgical re-exploration.2 
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2. REVIEW OF LITERATURE 
2.1 Nephron 
Each kidney contains 1.0 to 1.3 million nephrons, the functional units of the kidney 
(Figure 1.). In the nephron blood enters the glomerulus via an afferent arteriole and exits 
through an efferent arteriole. The glomerular blood pressure acts as a driving force for 
water, amino acids, and free ions to be filtered out from the blood and into the space made 
by the glomerular capsule (Bowman’s capsule). Fluid then flows to the renal tubule, which 
consist of the proximal convoluted tubule, the loop of Henle, and the distal convoluted 
tubule. The main function of the proximal tubule is to resorb Na+ and water, but 
bicarbonate, Cl-, glucose, amino acids, phosphate, and lactate are also transported. The 
main function of the loop of Henle is to create and maintain concentration gradient of 
osmolality within the renal medullary interstitium. This provides the downstream 
collecting ducts ability to concentrate urine by osmosis. The resorption of Ca2+ and Mg2+ 
occurs also in the loop of Henle. The distal convoluted tubule delivers its filtrate to a 
system of collecting ducts and is also responsible for subtle changes in Na+, K+, Ca2+, 
phosphate, and acid-base homeostasis. The collecting ducts run down the steep 
concentration gradient created by the loop of Henle allowing water resorption. This leads 
in the creation of concentrated, hypertonic urine.17 
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2.2. Acute Kidney Injury (AKI) 
2.2.1. Definition of Acute Kidney Injury  
The current definition of acute kidney injury is an abrupt and sustained decrease in renal 
function resulting in retention of nitrogenous products, such as creatinine and urea.18 The 
kidney is a complex organ responsible to various functions. Depending on the duration 
and severity of AKI it can lead to disturbances in salt and water regulation, toxin and 
metabolite elimination, electrolyte homeostasis, and acid-base balance.19 There is also 
growing evidence for the direct negative impact of AKI on other vital organs.20  
 
Several definitions of the diagnosis of acute renal failure have been employed, usually 
including absolute or relative changes in creatinine, glomerular filtration rate values, and 
reduction of urine output.  Generally, the studies have measured the incidence of acute 
renal failure as a loss or near loss of kidney function and requirement of RRT. However, 
while it was recognized that even smaller changes in creatinine values have affected short- 
and long-term outcome of the AKI patients, the development of more sensitive definition 
of kidney dysfunction was needed. During the search for new criteria the term acute renal 
failure was replaced with a more accurate expression acute kidney injury. In 2002 the 
ADQI group started to develop the consensus of AKI with the definition known as RIFLE, 
which included 3 different severity stages; risk, injury and failure, and 2 outcome stages; 
loss of kidney function and end-stage kidney disease. These stages were based on the 
degree of increase in serum creatinine level or the duration of oliguria, the risk and injury 
stages increased the sensitivity to define AKI when the failure was a specific stage.21 This 
definition was modified by the AKIN group by the addition of an absolute increase in 
serum creatinine level of more than 26.5 μmol/l and shortening the time limit for AKI 
diagnosis from 7 days to 48 hours and removing the two outcome stages (Table 1).6 In 
validation studies with CSA-AKI patients both definitions have demonstrated increased 
mortality risk associated with progressively more severe stages of AKI.22 During the past 
decade the consensus of the AKI criteria has been developing and according to the latest 
consensus by KDIGO, AKI is defined as an increase in serum creatinine levels of 26.4 
μmol/l or greater within 48 hours, or an increase of serum creatinine more than 1.5 times 
the baseline within 7 days, or diuresis less than 0.5 ml/kg/h for 6 hours.23   
 
All RIFLE, AKIN, and KDIGO criteria include urine output in the definition of AKI. 
This has been criticized because oliguria may be an appropriate response to volume 
depletion rather than a symptom of declined renal function. Further, the weight-based 
definition for AKI limits its use in the obese because of the disproportion between the 
weight and urine output, and urine output can be manipulated such drugs as diuretics and 
dopamine.24 A majority of studies use only creatinine criterion for AKI diagnosis, 
furthermore, the evaluation of studies using both urine output and creatinine have shown 
poor correlation between these criteria.25 However, in a study with critically ill patients it 
was demonstrated that the use of RIFLE criteria without urine output criteria significantly 
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underestimated the incidence and grade of AKI, AKI diagnosis was delayed, and it was 
associated with higher mortality.26 All three AKI definitions have limitations. They rely 
on creatinine as it is not an ideal biomarker for AKI, it is also affected by factors 
independent of GFR, such as age, gender, body weight, and drugs.27 None of the 
definitions indicates the origin of the kidney injury. 
Table 1. Comparison of RIFLE, AKIN, and KDIGO classifications of acute kidney injury 
 Rifle  AKIN KDIGO 
Definition S-Cr > 1.5 x baseline 
 over ≤ 7 days 
 S-Cr > 1.5 x baseline 
over ≤ 48 hours 
S-Cr > 1.5 x baseline  
over ≤ 7 days 
Class  Stage   
Risk S-Cr > 1.5 x baseline 
 
  
         
1 
S-Cr > 1.5 x baseline 
or 
?S-Cr ≥ 26.5 μmol/l  
 
S-Cr > 1.5 x baseline 
or 
?S-Cr ≥ 26.5 μmol/l  
 
 UO < 0.5 ml/kg/h x 6 
h 
 
 UO < 0.5 ml/kg/h x 6 
h 
 
UO < 0.5 ml/kg/h x 6 h 
 
   
?GFR  > 25% 
 
   
Injury S-Cr > 2 x baseline 
 
 
 
         
2 
S-Cr > 2 x baseline 
 
S-Cr > 2 x baseline 
 
 UO < 0.5 ml/kg/h x 
12 h 
 
 UO < 0.5 ml/kg/h x 12 
h 
 
UO < 0.5 ml/kg/h x 12 h 
 
 ?GFR  > 50 % 
 
   
                   
Failure 
S-Cr > 3 x baseline 
or 
?S-Cr ≥ 353.6 
μmol/l, with acute 
rise of 
≥ 44.2 μmol/l 
 
?GFR  > 75 % 
 
         
3 
S-Cr > 3 x baseline 
or  
?S-Cr ≥ 353.6 
μmol/l, with acute rise 
of ≥ 44.2 μmol/l 
 
S-Cr > 3 x baseline 
or 
?S-Cr ≥ 353.6 μmol/l 
 
 UO < 0.3 ml/kg/h x 
24 h 
or 
anuria x 12 h 
 
 UO < 0.3 ml/kg/h x 24 
h 
or 
anuria x 12 h 
 
UO < 0.3 ml/kg/h x 24 h 
or 
anuria x 12 h 
 
 ?GFR  > 75 % 
 
   
   Initiation of RRT Initiation of RRT 
 Loss RRT required for > 4 
weeks 
   
End      
stage 
RRT required for > 4 
months 
   
 
 
 
 
 
17
2.2.2. Incidence and outcome of cardiac CSA-AKI 
According to RIFLE and AKIN criteria, the range of CSA-AKI incidence is between 9 to 
39 %. The observed incidence depends on the clinical profile of the analyzed patients and 
on the type of surgery. Isolated coronary artery bypass grafting (CABG) has the lowest 
incidence of AKI, 2 to 5%, whereas in valve or combined valve and CABG surgery AKI 
occurs in up to 30% of patients.9 In patients with known risk factors for kidney injury the 
incidence of AKI may increase to as high as 50%.28 The requirement of RRT in patients 
with CSA-AKI is 1 to 5%.29-32 Postoperative renal dysfunction develops even more often 
in heart transplant patients, the incidence of AKI being 70%, of which 6 to 25% receive 
RRT before hospital discharge.3336 RIFLE and AKIN has been tested for better clinical 
accuracy of CSA-AKI, and the investigators discovered that both criteria showed good 
correlation with mortality, but significantly more patients were diagnosed by AKIN than 
by RIFLE. It was suggested that AKIN, applied in cardiac surgery patients without 
correction of serum creatinine for fluid balance, may lead to over diagnosis of AKI.8  
 
During hospitalization, CSA-AKI is strongly associated with increased mortality, 
morbidity, and the length of hospital stay, and it affects the long-term survival.37,38 The 
incidence of AKI has increased over time, partly due to different definitions of AKI, but 
the survival of the CSA-AKI has improved. During the period of 1993-2002 the associated 
mortality has decreased from 32% to 23%. The short-term mortality in patients needing 
RRT has also decreased from 61% to 49% but there is no improvement in long-term 
survival in this group.39 Even a small increase in postoperative serum creatinine is 
associated with increased mortality, both in short- and long-term follow-up. A decrease in 
postoperative serum creatinine is associated with reduced mortality but even a small or 
subclinical increase in creatinine increases 30-day mortality.3,40 Patients suffering stage I 
AKI (RIFLE) had higher mortality, higher incidence of neurological dysfunction, longer 
duration of mechanical ventilation, and longer stay in the ICU and in hospital.41 Even 
when the renal function is recovered, the small elevation in postoperative serum creatinine 
is associated with increased long-term mortality.42 The extent of postoperative creatinine 
increase is associated with an increased risk to develop chronic kidney disease, and even a 
small elevation of creatinine is meaningful.43 Finally, the duration of AKI seems to be 
directly proportional to long term mortality.7  
2.3. Pathophysiology of AKI 
2.3.1. Pathophysiology of AKI 
Primary causes of AKI in hospitalized patients include ischemia or nephrotoxity.18 
Clinically AKI is broadly divided into three categories: prerenal, renal, and postrenal. 
Postrenal AKI is caused by obstruction of the urinary collection system.  Prerenal AKI 
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results from decreased renal perfusion, which leads to a reduction in glomerular filtration 
rate (GFR), which is seen as an increase in serum creatinine. Primary causes leading to 
prerenal AKI are a failure in general circulation, or isolated failure of the intrarenal 
circulation caused by hypovolemia, low cardiac output, decreased vascular resistance or 
occlusion in the renal artery.44 The kidney is able to autoregulate renal blood flow within 
limited boundaries. Blood flow to the glomerulus is regulated by the preglomerular 
afferent and postglomerular efferent arteriolar sphincter tone. During hypotension, 
vasodilatation of the afferent arterioles occurs mediated by prostaglandin I2 and nitric 
oxide generated within the kidney, and the concomitant vasoconstriction of the efferent 
arterioles is mainly induced by angiotensin II. These adjustments attempt to maintain the 
glomerular capillary hydrostatic pressure.45,46 In acute hypovolemia the tubuloglomerular 
feedback mechanism is initiated to stabilize GFR and fluid delivery to the distal nephron, 
and this process is mediated by complex interaction between the macula densa and the 
glomerular microvasculature.47 Prerenal AKI can be reversed in hours or days if the 
circulatory failure and renal hypoperfusion are promptly corrected, otherwise persistent 
hypoperfusion will lead to intrinsic renal failure.   
2.3.2. Acute tubular necrosis (ATN) 
In the intrinsic renal failure a wide variety of injuries can occur to the kidney. To 
comprehend the different etiologies the kidney is generally divided in to four major 
structures that can be damaged: the tubules, the glomeruli, the interstitium, and the 
intrarenal blood vessels.18 The tubular damage, acute tubular necrosis, is the main cause of 
AKI in patients with major surgery or in critically ill patients.44 Major causes of ATN are 
ischemia-hypoxia and nephrotoxicity (Figure 2). The nephrotoxic damage is caused by a 
variety of exogenous compounds (aminoglycosides, radio contrast media), and 
endogenous compounds (free hemoglobin, myoglobin).18 However, the term ATP has 
recently been challenged, because there is a contradiction concerning the severe clinical 
syndrome of kidney injury and lack of histopathological findings that could be linked 
together.48 Investigators emphasized the role of endothelial dysfunction, coagulation 
abnormalities, systemic inflammation, and oxidative stress in the role of AKI, rather than 
the term ATN. Also, much of the current understanding of the pathophysiology of AKI is 
derived from animal research, but this setting rarely applies to the clinical events and more 
relevant models are needed. 48  
 
Normally the kidneys receive 25% of cardiac output, but the renal blood flow is not 
homogeneously distributed within the organ. The cortex and the cortical nephrons receive 
90% of the renal blood flow, when the medulla and the juxtamedullary nephrons receive 
only 10 % of the renal blood flow. If the partial oxygen pressure in the cortex tissue 
decreases, it results in borderline chronic oxygen deprivation of the highly metabolically 
active cells in the S3 segment of the proximal tubule and the medullary thick ascending 
limbs.49   
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 In ATN renal tubular epithelial cells undergo rather sublethal changes than actual 
necrosis, thus lately it has been suggested that tubular injury might be a better term. 
Although, clear evidence is absent to indicate connection of GFR and tubular injury, 
clinically ATN has been divided into different phases according to changes at cellular 
level and GFR. The phases are initiation, extension, maintenance, and recovery.18 During 
the early stage of renal ischemia, cellular and vascular adaptations in the kidneys maintain 
renal epithelial stability, but when further fall in renal blood flow persists, the initiation 
phase occurs and tubular epithelial cells suffer from injury and dysfunction. The extension 
phase is characterized by continued hypoxia and inflammation, and both of these are more 
pronounced in the corticomedullary junction. GFR further decreases when injury, 
necrosis, and apoptosis are present in the outer medulla, while proximal tubule cells in 
outer cortex, where blood flow has returned, undergo cellular repair. In the maintenance 
phase GFR reaches its nadir value, and cells undergo repair process, migration, apoptosis, 
proliferation, and differentiation in order to re-establish and maintain cellular and tubular 
integrity. In the recovery phase cellular differentiation proceeds, epithelial polarity is re-
established and normal cell and kidney function leads to increased GFR.50 Delay or 
inhibition of this repair process can lead to progression of injury and eventually lead to 
development of chronic kidney injury.51  
 
Decrease in GFR results from microvascular and tubular changes in the kidney. Renal 
vasoconstriction and loss of autoregulation lead to alteration in renal blood flow. Sublethal 
tubular damage impairs reabsorption of sodium, and activates the potent vasoconstrictor, 
as well as a potent vasoconstrictor adenosine, resulting in afferent arteriolar 
vasoconstriction, and related decrease in GFR. Concomitant sympathetic nerve activity 
and stimulated renin and angiotensin II secretion further increase the vasoconstriction. In 
addition, elevated levels of endothelin, another potent vasoconstrictor, levels have been 
reported in patients with AKI.18 Ischemia-reperfusion injury promotes leukocyte adhesion 
to activated endothelial cells. This is proposed to impair capillary flow, generate 
molecules increasing vasoconstriction, cause a parenchymal cell injury, and possibly 
increase tubular lumen pressure and reduce GFR. These factors may contribute to the 
resistance to vasodilatory therapy in the extension phase of AKI.18 The immune response 
to AKI is complex and involves cells of the innate and adaptive immune systems, the 
innate immune cells such as neutrophils, macrophages, dendritic cells, natural killer cells, 
natural killer T cells, and adaptive CD4+T cells promote renal injury.52 The role of 
lymphocytes, T and B cells, the major effector cells in adaptive immune system, can be 
either to promote AKI or protect against ischemia-reperfusion injury.52 Regulatory T cells 
act as a counterbalance to the pro-inflammatory cells by producing anti-inflammatory 
cytokines, generating extracellular adenosine and promoting inhibition of dendritic cells.52  
 
At tubular cellular level ischemia results in a rapid loss of cytoskeletal integrity and 
cell polarity, with shedding of proximal tubule brush border, mislocalization of adhesion 
molecules and other proteins, such as sodium/potassium ATPase and β-integrins, along 
with apoptosis and necrosis.53 In severe injury, viable and non-viable cells are 
desquamated, leaving regions of basement membrane, the only barrier between the filtrate 
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and peritubular interstitium, and resulting possible back-leak of the filtrate. This can be 
augmented by cellular debris, which can cause intratubular obstruction and increase the 
pressure in tubule.53 The epithelial injury in tubular cells promotes the generation of 
inflammatory and vasoactive mediators which can increase the vasoconstriction and 
further elevate inflammation and thus play a pivotal role in AKI.53  
 
 ?????????? ?????????????????????????????????
2.4.  Pathophysiology of CSA-AKI 
Multiple and complex pathophysiological features are thought to participate in CSA-AKI. 
ADQI consensus meeting has addressed AKI in cardiac surgery and drawn up statements 
considering the pathophysiology and treatment of AKI.11 Based on available evidence 
numerous mechanisms, processes, and pathways were suggested: exogenous and 
endogenous toxins, metabolic factors, ischemia-reperfusion injury, neurohormonal 
activation, inflammation, and oxidative stress. During the cardiac surgery these different 
processes of injury can occur frequently at different times and also overlap with each other 
leading to AKI. Table 2 presents factors of CSA-AKI.  
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Preoperative Intraoperative Postoperative 
   
Co- morbidities Type of surgery Cardiac low output 
Atherosclerotic disease Emboli SIRS 
Diabetes CPB Transfusion 
CKD Hypoperfusion  
Heart failure SIRS  
Embolism Hemodilution  
Nephrotoxins Hemolysis  
Contrasts media Transfusion  
Other drugs   
 
Table 2. Pathophysiological factors in cardiac surgery associated acute kidney injury. CKD; 
chronic kidney disease, CPB; cardio pulmonary bypass, SIRS; systemic inflammatory response 
syndrome. 
2.4.1. Preoperative period 
Preoperative risks for kidney injury are frequently patient derived, or a result of treatment 
of the cardiovascular disease.  The co-morbidities, as atherosclerotic disease, diabetes, 
chronic kidney disease, and heart failure, are common, and they likely increase the risk for 
AKI. The emergent or urgent cardiac operation predisposes patients to several potentially 
detrimental effects on their kidneys, which further increase the risk of AKI.11  
 
During this period cardiogenic shock is the most plausible cause to ischemia 
reperfusion injury to kidneys. In heart failure, caused by myocardial infarction or severe 
valvular disease, low cardiac output is a direct cause to renal hypoperfusion and AKI. This 
insult can be exacerbated by the administration of diuretics, non-steroidal anti-
inflammatory drugs (NSAIDs), angiotensin-converting enzyme inhibitors (ACEIs), or 
angiotensin receptor blockers (ARBs), these drugs may impair the autoregulation of renal 
blood flow.54 The treatment of low-output patients commonly includes vasodilators and 
diuretics, which may lead to dehydration, hypovolemia, and hypotension.11  
 
Renal artery embolism originating from intracardiac thrombus, vegetation of a valve, 
or atherosclerotic plaque leads to unexpected impaired renal perfusion. Especially during 
cardiac catheterization atherosclerotic emboli can be produced leading to a blockade of the 
renal artery impairing the renal circulation for an uncertain period of time.55 Due to the 
fact that the thrombi may dissolve, or collateral flow may restore the blood flow to the 
kidneys, the adverse event is difficult to recognize and the ischemia time is unknown. 
Atherosclerotic disease itself manifested as renal artery stenosis can also affect renal 
perfusion, particularly during hypotension. 
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Another reason for hypotension is allergic reaction with anaphylactic features caused 
by antibiotics or other medication given to the patient preoperatively. The treatment of 
hypotension may be further complicated because of previously administrated 
vasodilators.11 
 
The inflammatory system is activated in the preoperative period by atherosclerotic 
heart disease and infections, mainly endocarditis. There are some studies showing 
correlation with elevated inflammatory mediators and adverse outcome after cardiac 
surgery, but none has addressed the preoperative inflammation and renal function.56 Some 
studies have indicated that statins may reduce inflammation and improve endothelial 
function, but there is no evidence that they reduce AKI in cardiac surgery. 57,58 However, 
in a recent study with 625 patients divided into two groups to continue preoperative statins 
versus to discontinue them for 24 hours, the battery of renal biomarkers were significantly 
decreased with patients continuing statins, although there was no difference in AKI 
defined by doubling of serum creatinine or requirement of RRT.59 
 
In chronic heart failure, the neurohormonal activation may increase the risk in cardiac 
surgery. In cardiac low output failure the renal blood flow is decreased, which activates 
the renin-angiotensin-aldosterone system and the sympathetic nervous system. It also 
increases production of antidiuretic hormone, induces inflammatory mediators, and affects 
endothelium by reducing nitric oxide production resulting in vasoconstriction and a 
decrease in the renal blood flow leading to reduced renal filtration and sodium and water 
retention.60 Other co-existing diseases, as hypertension, and diabetes or therapies such as 
ACEIs, ARBs, and diuretics, might further increase the risk of AKI. These patients often 
have chronic kidney disease preoperatively. 
 
During the preoperative period some other nephrotoxic drugs administrated to the 
patients may increase renal dysfunction. Endocarditis may be treated with antibiotics like 
beta-lactam, aminoglycoside, or amphotericin B, which can cause direct injury or 
interstitial nephropathy.61 More common is radio contrast-induced nephropathy. Iodinated 
contrast media can cause a renal insult by inducing vasoconstriction and exposing tubular 
cells to direct toxic effects, and simultaneous oxidative stress and inflammation may both 
add injury to the kidneys. Patients with chronic kidney disease are more susceptible to 
additional injury during catheterization. 62 Cardiac surgery performed less than 24 hours 
after cardiac catheterization has been demonstrated to cause renal dysfunction in coronary 
artery bypass patients.63 
2.4.2. Intraoperative period 
During intraoperative period patients are exposed to anesthesia and cardiopulmonary 
bypass, which can cause hypotension and activate the immune system. The manipulation 
and cannulation of the aorta can release emboli to circulation before the initiation of the 
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CPB.11 The use of epi-aortic echocardiography before cannulation and clamping of the 
aorta has demonstrated to be beneficial to detect plaques in the ascending aorta.64  
 
Pump flow during CPB 
 The introduction of cardiopulmonary bypass machine more than 60 years ago made 
complex cardiac surgery possible without high risk, but already in the 1960s the 
association between CPB and kidney injury became apparent.65 The materials and the 
techniques have improved, but CPB is still considered to have a vast influence on the 
postoperative kidney function of cardiac surgery patients. 
The goal of CPB is to maintain regional perfusion at a level that supports optimal organ 
function.66 CPB flow rate recommendation 1.8-2.2 l/min/m2 is based on experimental 
calculations of global oxygen consumption at different perfusion rates.67 However, it is 
not known what the regional flow rates are with this recommendation, and generally flow 
rates are maintained at the level of normal cardiac index, 2.2-2.4 l/min/m2. There is debate 
whether a pulsatile flow preserves kidney function better than a non-pulsatile flow in 
CPB. In one large study pulsatile flow demonstrated no protection to kidneys as compared 
to non-pulsatile flow.68 However, another more recent research showed less acute renal 
insufficiency and significantly improved whole body perfusion in the elderly undergoing 
CPB with intra-aortic balloon pump (IABP) induced pulsatile flow.69 Despite the 
theoretical benefits of the pulsatile flow, almost all centers perform CPB using non-
pulsatile pumps. 
 
Perfusion pressure during CPB 
The flow rate and the perfusion pressure determine regional blood flow in CPB. The ideal 
perfusion pressure to secure sufficient local oxygen delivery to kidneys is unknown, and 
generally a mean perfusion pressure of 50 to 70 mmHg with normal cardiac output is 
maintained to ensure adequate renal protection.70 Furthermore, it is unknown if these 
recommended flow rates and pressure limits are adequate to preserve renal blood flow in 
patients with preoperative kidney injury, or in patients with pre-existing ATN and possible 
loss of autoregulation.70 One study looked at CPB mean arterial pressure (MAP) ranges of 
40 to 80 mmHg in elderly patients and found no correlation to postoperative renal 
dysfunction.71 A study in patients with normal preoperative renal function showed 
association between postoperative AKI and longer CPB time, lower perfusion flow, and 
longer periods on CPB at pressures below 60 mmHg.72 Ono et al. measured the excursions 
of MAP during CBP below the limit of autoregulation, and found that MAP at the limit of 
autoregulation and the duration and degree to which MAP was below the autoregulation 
threshold were independently associated with AKI, although the absolute MAP did not 
differ between the patients with AKI and the patients without kidney injury.73 In addition, 
it was demonstrated that MAP variance (preoperative MAP minus intraoperative MAP) 
more than 26 mmHg was independently associated with AKI in high-risk patients.74 
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Hypothermia during CPB 
For organ protection, most procedures performed with CPB employ mild to moderate 
systemic hypothermia (32-36° C), and more challenging operations may require deep 
hypothermia (15-25° C) to allow periods of low blood low or circulatory arrest. However, 
there are conflicting results of hypothermia versus normothermia with regard to renal 
outcome. One reason for this may be the different sites for temperature monitoring. 
Bladder, nasopharynx, and blood temperatures may differ several degrees from each other, 
depending on patient’s body habitus and surrounding temperature. The arterial 
temperature seems to be closest to jugular bulb temperature, which reflects the 
temperature of   the central nervous system.75 In a recent study, patients on CPB were 
cooled to 32°C and rewarmed to 34°C or to 37°C.76 The patient group warmed to 37°C 
had higher incidence of AKI. Another patient group was sustained in mild hypothermia 
34°C, which did not improve the renal outcome.76 Rewarming, rather than hypothermia, of 
patients on CPB had more impact on renal outcome, suggesting that rewarming speed may 
be an important factor to sustain balance of oxygen supply and demand on CPB. 
 
Embolism during CPB 
During CPB both gaseous and particulate emboli are generated and may lead to organ 
injury. The correlation between the number of cerebral emboli and postoperative stroke 
and kidney injury has been demonstrated.77 When pulses of embolic signals were 
registered with transcranial Doppler, pulses of embolic signals were obtained during aortic 
manipulation, suggesting that atherosclerotic aorta is a risk for stroke and AKI.77 Air is 
another source of emboli.  It may enter to the left side of heart when left side of the heart 
is open, for example during valve surgery, or enter from the right side through open 
foramen ovale. “De-airing”-maneuvers are applied to remove the air, and the use of 
carbon dioxide aids to remove trapped air from the heart as it is more soluble in blood than 
nitrogen, the main component of air. 78 Echocardiography is helpful to detect, and to aid 
the removal, of residual air.79 
 
Inflammatory system 
CPB activates a systemic inflammatory response, which in some patients clinically 
manifest as a syndrome (SIRS).80 Cardiac surgery with CPB pump elevates more systemic 
inflammatory factors than off-pump operations implicating that CPB itself provokes 
SIRS.81 The main triggers of CPB-associated SIRS is the direct contact of blood with the 
artificial surface of the bypass circuit, development of ischemia-reperfusion injury, and 
presence of endotoxemia.82-84 Other possible provoking factors are, operative trauma, non-
pulsatile blood flow, mediastinal shed blood during CPB, and pre-existing left ventricular 
dysfunction.70 The increased level of circulating inflammatory mediators may elicit 
endothelial dysfunction and the initiation of AKI amplified by alterations in renal 
perfusion.85 The AKI patients demonstrated significantly greater increase in neutrophil 
CD11b (neutrophil adhesion receptor) density, as well as higher total neutrophil counts, in 
a study of the markers of leukocyte and platelet activation during CPB. However, 
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neutrophil CD11b upregulation did not correlate with other clinical variables associated 
with renal risk, suggesting that this marker of neutrophil inflammatory response may 
independently predict kidney injury.86 Further, in this study other inflammatory markers 
did not differ between patients with AKI and patients without kidney injury. In a small 
prospective trial with low-risk patients, the group without leukocyte depletion suffered 
more injury to both renal tubules and glomeruli, than patients with leukocyte depletion, 
suggesting that leukocytes may also have an important role in post CPB AKI.87 
Prolonged CPB and cross-clamp time of aorta associates strongly with increased 
incidence of AKI, although safe time limit has not been determined.88 Adverse events as 
SIRS and hemolysis generated by CPB are plausible reasons for increased risk of AKI. 
A recent meta-analysis analyzed the randomized controlled trials of anti-inflammatory 
strategies in aim to reduce AKI in cardiac surgery patients.89 Based on previous findings 
they included trials that used interventions as glucocorticoid administration, leukocyte 
filter application, and minimizedextracorporeal circuits to modulate inflammatory 
response, and only leukocyte filters effectively reduced worsening of the renal function.89 
The role of inflammation in CSA-AKI is based mainly on animal models of renal 
ischemia–reperfusion injury, and they clearly demonstrate the role of interstitial 
inflammation and the elaboration of pro-inflammatory cytokines, as well as reactive 
oxygen species, in the production of tubular injury.70 However, large clinical, randomized, 
and controled trials are needed in order to better evaluate the role of inflammation in CSA-
AKI. 
 
Hemodilution 
Hemodilution occurs at the initiation of CPB decreasing blood viscosity and improving 
regional blood flow in the setting of hypoperfusion and hypothermia. Anemia, when 
hematocrit is less than 21% to 24% during CPB, has been reported to increase the risk of 
postoperative AKI.90 AKI risk appeared to increase, when both anemia and hypotension 
occurred during CPB, compared with anemia alone.91 Another study could not confirm 
this result, and it has also been noted, that the harmful effects of anemia could be reduced 
by increasing the oxygen delivery by increasing the pump flow.92,93  
 
Hemolysis 
A common consequence of CPB is the development of intravascular hemolysis.94 In 
hemolysis there are several contributing factors to kidney injury, as loss of red blood cell 
(RBC) mass, impaired endothelial function, oxidative damage, and cytotoxic tubular 
damage.95 Haptoglobin scavenges circulating free hemoglobin (fHb), but when its capacity 
is saturated, fHb binds to nitric oxide (NO) derived from endothelium, leading to 
decreased NO-bioavailability, consequently increasing vascular resistance and decreasing 
organ perfusion.96 In a recent study with cardiac surgery patients there was a significant 
correlation between hemolysis, NO consumption, and kidney tissue damage after CPB and 
surgery.97 Furthermore, the structure of RBCs can also be damaged, which diminishes 
their ability to enter in small vessels and reduces their contact with vessel walls, leading to 
organ ischemia.94 
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In a setting of CPB, several mechanisms contribute to the destruction of RBCs: shear 
stress, blood-air and blood-endothelial interface, and positive and negative pressures. The 
primary source of fHb is the suction from the operative field and active suction from heart 
chambers. The amount of air that is aspirated together with the blood increases red cell 
fragility.98 CPB time is also directly related to the degree of hemolysis.99 There is no 
evidence of superiority of the rollers versus centrifugal pumps with respect to hemolysis.94 
The suggested strategies to prevent hemolysis during CBP are to avoid excessive use of 
suction, to use a separate cardiotomy reservoir to avoid damaged RBCs and fHb, to 
administer haptoglobin or NO-donors to compensate for the enhanced NO consumption, 
and to apply a super high-flux hemofilter to remove fHb.95 
During CPB blood sucked from the operative field can be collected to the venous 
reservoir and returned directly to the patient through the bypass circuit or after processing 
blood with a cell saving device. Cell saving device retains RBCs and removes fHb, 
inflammatory mediators, fat emboli, and heparin, but also plasma and platelets. At present 
there is no evidence that this cell saving technique has effect on renal outcome after 
cardiac surgery.95 
 
Transfusion 
Perioperative RBC transfusion is considered to be a risk factor to AKI in susceptible 
patients, such as those with preoperative kidney disease or anemia.100 Especially more 
than 14 days stored RBCs became less formable, undergo ATP and 2,3-
diphosphoglycerate depletion, lose their ability to generate NO, have increased 
adhesiveness to vascular endothelium, release pro-coagulant phospholipids, and 
accumulate pro-inflammatory molecules and free iron and hemoglobin. Hence, instead of 
improving oxygen delivery, they may cause organ injury.101-104 Transfusion of stored 
RBCs may elicit harmful effects, such as inflammation, renal hypoxia, and oxidative 
stress.100 Patients with preoperative anemia are especially more susceptible to transfusion-
related AKI than nonanemic patients.105 In a recent study, prophylactic RBC transfusion 
reduced perioperative anemia and RBC transfusions, and possibly reduced plasma iron 
level.106 Interventions to avoid perioperative blood transfusion are recommended, such as 
drugs that increase preoperative blood volume or decrease postoperative bleeding, use of 
devices that conserve blood, and interventions that protect the patient’s own blood from 
the stress of operation.95  
 
Ultrafiltration during CPB 
Ultrafiltration is a standard method to remove fluid overload during CPB. It is commonly 
used in pediatric cardiac surgery and increasingly being employed also in adult cardiac 
surgery, both perioperatively and postoperatively. There is no data, however, whether this 
procedure improves renal outcome in adult cardiac surgery, but it is known that 
ultrafiltration minimizes the adverse effects of hemodilution, and consequently reduces the 
need for transfusion and also may decrease inflammation.107  
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2.4.3. Postoperative period 
Hemodynamic alterations are the most common occurrences to affect kidney function 
postoperatively. After weaning from the CPB some of the patients may suffer from 
cardiac low out-put, which necessitates hemodynamic support provided with inotropes, 
vasopressors, intra-aortic balloon pump (IABP), and occasionally even with a left 
ventricle assistance device (LAVD). These therapies may affect kidney perfusion, enhance 
inflammatory response, and combined with diuretics, may lead to inadequate circulating 
volume. 
 
IABP increases cardiac output by reducing left ventricle afterload and improving 
coronary perfusion. Occasionally it is inserted to high-risk patients in advance 
preoperatively, but may also be installed as a rescue therapy to wean patients from CPB. 
IABP has been independently associated with increased acute renal failure after cardiac 
surgery.108 On the other hand, in a meta-analysis study, preoperatively inserted IABP 
reduced hospital mortality in high-risk patients undergoing coronary bypass surgery.109 
The problem with intraoperatively placed IABP arises if the patient presents with 
atherosclerotic aorta. In a retrospective study the patients with IABP and atherosclerotic 
descending thoracic aorta, had significantly increased the risk of developing AKI and 
higher hospital mortality, as compared to the patients without IABP and descending 
thoracic aorta atheroma.110 
 
Cardiac tamponade may also cause circulatory changes after cardiac surgery. The 
symptoms of postoperative tamponade are variable, which can make it difficult to 
recognize requiring often echocardiography to confirm the diagnosis. Tamponade and 
excessive bleeding leads to re-exploration, which is associated with adverse outcomes.111 
In a recent report re-exploration caused higher transfusions requirements and led to 
increased postoperative AKI.112 In a further analysis writers found, that not the re-
exploration itself, but the blood loss and transfusion were independent risk factors for 
mortality, which was also higher when re-exploration was delayed and when tamponade 
was the indication of re-exploration.112 
Postoperatively administered nephrotoxic drugs present an additional risk for kidney 
injury. Calcineurin inhibitors, given after heart transplantation as immunosuppressives, are 
associated with postoperative AKI.113   
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2.5. Measurement of renal function 
2.5.1 Creatinine 
The renal clearance of a substance is the volume of plasma completely cleared of a 
substance per unit time. 
C = U × V/P 
where C = clearance in ml/min; U = urine concentration in mg/min; V = urine 
volume/time in ml/min; P = plasma concentration in mg/ml. 
Glomerular filtration rate is considered to be the sum of the filtration rates for all 
functioning nephrons in kidneys. It can differ depending on age, sex, race, and muscle 
mass, and it may show inter-individual and intra-individual variation.13 GFR is classically 
measured as renal clearance of inulin, which is considered as a perfect filtration marker 
because it is freely filterable at the glomerulus, not reabsorbed, secreted, or metabolized 
by the renal tubule, not bound to plasma proteins, nontoxic, and physiologically inert.27 
Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine per 
unit time. It is less accurate than inulin clearance, but more practical to measure.  
 
GFR ≈ Ucreatinine  × V / Pcreatinine = Ccreatinine   
 
where GFR = glomerular filtration rate in ml/min, Ucreatinine = urine concentration of 
creatinine in mg/ml; V = urine flow rate in ml/min; Pcreatinine  = plasma concentration of 
creatinine in mg/ml; Ccreatinine  = clearance of  creatinine in ml/min. 
In healthy and young people the normal GFR is about 120 ml/min/ per 1.73m2 of body 
surface area in men and 100 ml/min/1.73m2 in women.27 Although inulin is considered an 
accurate marker of filtration, the measurement is complex, expensive, and impractical in 
clinical use.114 Serum creatinine is the standard measurement, although it is not the ideal 
marker. The serum concentration of creatinine is affected by age, gender, muscle mass, 
medication, and circulating volume status, and moreover, the serum concentration may 
start to increase when almost 50% of kidney function have already been lost.27 The GFR 
measurements with creatinine necessitate 24-hour urine collection and steady state, which 
rarely exists in the acute setting, and thus different equations have been presented to 
estimate the GFR in clinical use. The Modification of Diet in Renal Disease (MDRD) 
equation has been the most frequently applied formula, but recently it was replaced with 
equation by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), the 
formulas are presented in equations a and b, respectively:115,116  
 
a. GFR (ml/min/1.73m2) = 186 x Cr(-1.154) x Age(-0.203) x (0.742 for females) x (1.212 
for Afro-Americans) 
b. GFR (ml/min/1.73m2) = 141 x min (Cr/ κ, 1)α x max (Cr/ κ, 1)-1.209 x 0.993age x 
(1.018 for females) x (1.159 for Afro-Americans) 
 Cr = Serum creatinine (mg/dl); κ = 0.7 if female or 0.9 if male; α = -0.329 if female or                
-0.411 if male; min = minimum SCr/κ or 1; max = maximum SCr/κ or 1 
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The MDRD equation is 4-variable, as the original formula used six variables including 
blood urea nitrogen and albumin in addition to serum creatinine, age, ethnicity, and 
gender.117 The CKD-EPI equation was developed to be more accurate than the MDRD 
formula, especially when the actual GFR is greater than 60 ml/kg/1.73m2.116 Creatinine 
continues to be the index marker for the renal function despite its lack of sensitivity. The 
RIFLE criteria apply serum creatinine, MDRD equation, and urine output to define renal 
dysfunction, although they use the change of creatinine values, not the absolute values in 
themselves.118  
2.5.2. Cystatin C 
Cystatin C has several attributes to make it an attractive filtration marker, and it has been 
challenging creatinine as a more sensitive marker for renal function.  It is a 13-kDa 
endogenous cystein proteinase inhibitor produced at a constant rate by all nucleated cells. 
It belongs to the family of proteins that has an important role in intracellular catabolism of 
various peptides and proteins.119,120 Cystatin C is almost totally filtered by the glomeruli, 
reabsorbed by proximal renal tubular cells, and catabolised. There is no significant protein 
binding.121,122 There is practically no detection of cystatin C in urine. When it can be 
measured, it may indicate tubular epithelial damage, and urine cystatin C has been 
proposed as a sensitive biomarker for AKI.123 Cystatin C is relatively stable, and it can be 
measured quickly and accurately with assays compatible with automatic analyzers, 
indicating that it is practical to clinical use.124 
 
Serum cystatin C concentrations have exhibited good inverse correlation with 
radionuclide-derived measurements of GFR.125 It has been claimed to be less sensitive 
than creatinine to patients’ age, sex, and muscle mass, and therefore a more accurate and 
sensitive marker for AKI.126,127 Cystatin C has been evaluated in populations at risk of 
chronic kidney disease in a number of studies, and it has performed similarly or better 
than creatinine.128,129 In a large cross-sectional study cystatin C concentration of less than 
1.12 mg/l was evaluated to be normal in 20 to 40 year olds without hypertension or 
diabetes mellitus. However, large studies have also revealed, that the cystatin C is affected 
besides age, also with male sex, smoking status, alcohol consumption, elevated C-reactive 
protein (CRP) levels, body muscle mass and adipose tissue, higher body mass index 
(BMI) was associated with higher cystatin C.130,131 In addition, cystatin C levels may be 
influenced by abnormal thyroid function and corticosteroid therapy.132,133 The influence of 
corticosteroids may be dose dependent. The cystatin C concentrations in patients treated in 
ICU or after cardiac surgery do not seem to be affected, but patients after organ transplant 
with high dose treatment of corticosteroids have elevated levels of cystatin C values when 
creatinine values had decreased.133-135  
 
Estimation equations of GFR based on cystatin C has in general proved to perform 
comparable to formulas based on creatinine.136-139 In acute setting estimated GFR 
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formulas seem to be less useful than in the diagnosis of chronic kidney disease. In a recent 
study with critically ill GFR was measured with inulin clearance, and GFR was estimated 
with four commonly used creatinine-based formulas, with five cystatin C based equations, 
and one equation combining cystatin C and serum creatinine, and in addition creatinine 
clearance was measured.140 The measured urinary creatinine clearance overestimated 
GFR, but also the estimates of creatinine based GFR had much bias, low accuracy, and 
precision. Formulas based on cystatin C were free of bias, but the accuracy and precision 
of the estimates were still inadequate.140  
 
Cystatin C in cardiac surgery 
Serum and urinary cystatin C have both been assessed in cardiac surgery for the prediction 
of early postoperative AKI in large cohort studies and in several small clinical studies 
(Table 3).141-145 Haase et al. investigated plasma cystatin C and plasma neutrophil 
gelatinase-associated lipocalin (NGAL) and their combination, in 100 adult cardiac 
surgery patients to evaluate their ability to predict the duration and severity of AKI.141 
They discovered that on arrival in intensive care unit cystatin C moderately correlated 
with these outcomes, however, when the patients with preoperative renal dysfunction were 
excluded the predictive capability of cystatin C was reduced while NGAL values remained 
the same.146 After 24 hours all the plasma creatinine values predicted AKI as well as 
cystatin C and NGAL.146 Wald et al. had a similar finding They measured plasma cystatin 
C preoperatively, 2 hours after the conclusion of CPB, and postoperative days one and 
two, and discovered that plasma cystatin C was higher at all times among patients with 
AKI.145 The preoperative cystatin C was elevated in patients who developed AKI, but the 
discriminatory capacity of cystatin C was modest when measured preoperatively and early 
after ending of CPB.145 In a large prospective multicenter cohort study plasma cystatin C 
and plasma creatinine were compared after cardiac surgery with high-risk patients, and 
creatinine detected more AKI patients than cystatin C.144 In this report AKI end points 
were defined by relative increase in creatinine and cystatin C from baseline, and the 
number of AKI patients was measured in 25%, 50%, and 100% increase of each marker. 
At every point there were more patients with AKI when measured with increase of 
creatinine, but there were no difference in clinical outcomes with these patients. However, 
the patients with AKI confirmed by both markers had considerably higher risk of the 
combined mortality/dialysis outcome than the patients with AKI detected by creatinine 
level alone.144 
 
Koyner et al. have measured urinary cystatin levels after cardiac surgery.142,143 First in 
a smaller study cystatin C and NGAL were analyzed postoperatively from plasma and 
urine, and urine cystatin C and NGAL predicted AKI better than plasma cystatin C and 
NGAL, which were considered useless predictors of AKI.142 Later in a large prospective 
multicenter cohort study urinary cystatin C was measured from 1203 adults and 299 
children within the first 12 hours after surgery.143 The early, 6 hours and 12 hours, 
postoperative measurements of urinary cystatin C correlated with both mild and severe 
AKI in both groups. However, when the analyses were adjusted for characteristics used 
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clinically for CSA-AKI stratification, the values did not associate significantly with the 
development of AKI.143 
 
There is evidence to suggest that pre-surgical cystatin C may predict postoperative 
AKI. In a small study GFR estimated from serum cystatin C, but not GFR estimated from 
serum creatinine, was an independent risk factor for hospital mortality and morbidity 
defined as prolonged postoperative stay in hospital.147 In a larger cohort study serum 
cystatin C proved to predict postoperative AKI better than creatinine or estimated GFR.148 
The writers adjusted the results with clinical predictors for CSA-AKI risk stratification 
and discovered that without the kidney markers the receiver operator characteristic (ROC) 
curve model for the outcome of AKI was 0.70, addition of cystatin C 0.72, and with the 
addition of creatinine 0.69.148 
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2.5.3. Kidney injury biomarkers  
Currently the only definitions of AKI are based on a rise in serum creatinine and a 
reduction in urine output. After cardiac surgery the changes in serum creatinine occur 
typically 48 hours after the insult to kidneys, when tubular injury has already occurred, 
and the diagnosis of AKI and interventions to prevent tubular necrosis will be delayed.95 
This has led to research on several novel biomarkers, which may assist earlier detection 
and prognosis prediction for CSA-AKI. The most studied biomarkers are NGAL, 
interleukin (IL-18), kidney injury molecule -1 (KIM-1), liver fatty acid–binding protein 
(L-FABP), and N-acetyl-β-glugosaminidase (NAG), or a combination of these markers.  
These biomarkers reflect different nature, magnitude, and site of injury based on their 
specifity.149 NGAL expression is up-regulated in kidney proximal tubule cells and urine 
following ischemic injury, IL-18 reflects an inflammatory process, and KIM-1 is a trans-
membrane receptor in tubules to aid the removal of apoptotic bodies. L-FABP is 
expressed in ischemic proximal tubule cells and protects kidneys by binding free fatty 
acids, and NAG is a sensitive, but not very specific, lysosomal enzyme, that even subtle 
alterations in the epithelial cells of the proximal tubules leads to increased secretion of 
NAG into the urine.51,149 
 
Recently in a large, multicenter cohort study in adults the function of NGAL, IL-18, 
KIM-1, and L-FABP were evaluated in cardiac surgery.150,151 All the studied biomarkers 
peaked within six hours after surgery, except KIM-1, which peaked two days after surgery 
and remained elevated for several days.151 The writers reported that urine IL-18 and 
plasma NGAL had the best ability to detect tubular injury leading later to clinical AKI, 
and only these biomarkers were helpful in predicting progression of AKI.151 In severe 
AKI, an area under the receiver-operating characteristics curve (AUROC) for each 
biomarker increased in magnitude, but only urine IL-18, NGAL, KIM-1, and plasma 
NGAL were associated with adverse outcomes, such as longer length of ICU treatment 
and hospital stay, and higher risk for dialysis or death.151 The AUC of clinical prediction 
model for AKI was 0.69, and urine IL-18 and plasma NGAL improved the AUROC to 
0.76 and 0.75, respectively.150 The combination of three biomarkers from two different 
time points also increased the AUROC for AKI up to 0.78.151 When analyzing the 
biomarkers’ association with three-year mortality after cardiac surgery, the investigators 
concluded that these biomarkers, especially IL-18 and KIM-1, correlated with mortality in 
patients with and without AKI.152  
 
Other studies have also tested biomarkers alone and in panel to evaluate their 
performance in SCA-AKI. In one study the AUROC values of urine KIM-1, NAG, and 
NGAL alone were between 0.61 and 0.67 to predict the development of AKI, and by 
combining these markers the AUROC increased to 0.78.153 In evaluation of 32 urine 
biomarkers to predict the progression of AKI in patients with AKIN stage 1 and 3 after 
cardiac surgery, IL-18 was the best predictor of worsening AKI or death, and L-FABP, 
NGAL, and KIM-1 were also good predictors of secondary outcome of AKIN stage 3 or 
death, but the combination of IL-18 and KIM-1 had an AUROC of 0.93 to predict AKIN 
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or death.154 The writers suggested that the combination of IL-18 and KIM-1 directs to 
identify high-risk patients for enrolment in clinical trials.154  
2.6. Preventing CSA-AKI 
2.6.1. Identification of high-risk patients (risk scores) 
There are several well studied, validated, and established independent risk factors for 
CSA-AKI. The most repeatedly observed risk factors include type of surgery, advanced 
age, female sex, reduced left ventricular function or congestive heart failure, diabetes 
mellitus, peripheral vascular disease, chronic obstructive pulmonary disease, anemia, 
emergency status, blood transfusions, reoperation, and preoperative renal impairment.2,3032 
The last factor, defined as GFR below 60 ml/min or creatinine over 185 μmol/l, is perhaps 
the most predictive of CSA-AKI.31 However, preoperative serum creatinine alone has 
proved to be a relatively poor discriminator to predict postoperative RRT after cardiac 
surgery.30 Advanced age and insulin-dependent diabetes have both been associated with 
glomerular sclerosis or chronic kidney disease, which makes these patients more 
susceptible to ischemic insults.155 The patients with unstable preoperative state often 
suffer from low cardiac output and reduced renal perfusion, which is further compromised 
during CPB, resulting in increased risk for AKI. Chronic lung disease increases the risk of 
prolonged ventilation, leading to possible infection, sepsis, and multi organ failure, 
including renal failure and RRT.30 A recent large study from Australia found also obesity 
and infective endocarditis to be significant risk factors for AKI within 30 days of cardiac 
surgery.156  
 
The risk of AKI increases when the surgical procedure includes CABG and valve 
instead of CABG alone. In a study by Mehta at al. the incidence of RRT occurred in 1.4% 
of all cardiac surgical patients, when it was 1.1% of CABG patients, and 5.1% of 
combined mitral valve and CABG patients.30 More complicated procedures increase the 
cross-clamp time of aorta and the duration of CPB, thus adding complications associated 
with CPB. To avoid the SIRS induced by CPB different coatings of the CPB system has 
been developed. Phosphorylcholine- and various heparin based, bioactive coated circuits 
aim to improve the bio-incompatibility of blood contact with artificial surface, but there is 
no evidence of the association between decreased CSA-AKI and coated circuits.95 
Different techniques have been developed to avoid CBP entirely in cardiac surgery. In off-
pump coronary artery bypass technique (OPCAB) CPB is avoided and aortic manipulation 
is minimized to attain more physiological renal perfusion and less systemic embolization, 
and less SIRS. After several large studies there is no sufficient evidence to prove the 
superiority of OPCAB versus CPB-CABG technique in regard to reduction of SCA-AKI. 
In a meta-analysis Niwegar at al. reported significant reduction in overall AKI and AKI 
requiring RRT (AKI-RRT) in OPCAB cases compared with on-pump CABG technique.157 
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But in two large randomized trials there was no significant difference between on-pump 
and off-pump techniques regarding AKI-RRT after 30 days follow up, but the other study 
found significantly less AKI at 30 days in OPCAB group.158,159 One reason, that there was 
no difference in the incidence of AKI-RRT in the study of Shroyer et al., may be that the 
patient population was not considered very high-risk for AKI.159 In a large retrospective 
study in elective patients with chronic kidney disease there was less death and incidence of 
RRT in the OPCAB group.160 It appears that patient selection may affect the results of 
OPCAB, and high-risk patients with chronic kidney disease may benefit from this 
technique. In valve surgery transcatheter aortic valve implantation (TAVI) technique has 
made it possible to avoid invasive surgery and CPB in high-risk patients. The incidence of 
AKI after TAVI ranges between 1.1 and 28%, depending on the definition of AKI.95 
Mortality in AKI patients after TAVI is 4 times higher than in patients without AKI.161 In 
a randomized trial with high-risk group of patients the incidence of AKI and need for RRT 
were similar in patients treated with TAVI and in patients with surgical aortic valve 
replacement at 30 days and 1 year.162 A new definition of AKI, modified from RIFLE, for 
TAVI patients was introduced in 2011.163 In a recent meta-analysis the incidence of AKI 
stage II-III was 7.5% with both definitions, and another study reported a 14.6% and 11.5% 
TAVI-AKI incidence according to new definition and RIFLE criteria, respectively.164,165 
Plausible causes of TAVI-AKI are associated with the use of contrast medium, 
hypotension during the procedure, and emboli in patients with severe atherosclerosis. The 
only predictor of AKI was blood transfusion in a study by Barbash et al.164  
 
Several validated risk-predictive models of CSA-AKI requiring RRT have been 
developed to identify patients at risk preoperatively. Chertow et al. were among the first to 
develop a risk index to predict postoperative need for RRT, but after that several 
prediction models have been published and validated.29 In risk-predictive model 
comparisons the Cleveland Clinic score has been most widely tested and it has performed 
to some extent better than the other models.166,167 It has also been validated in a single-
center cohort to predict not only AKI-RRT, but also milder AKI, defined as doubling of 
the baseline creatinine, and it performed well for both outcomes, AUROC being 0.86 and 
0.81, respectively.168 The Cleveland Clinic score (table 4) was formed on an analysis of 
total of 33 217 open-heart surgery patients.31 The score was based on 13 preoperative 
factors resulting in a range minimum of 0 to a maximum of 17 points, and patients with 
the lowest scores (0-2 points) had 0.4% risk of developing AKI requiring dialysis, while 
patients with highest score (9-13 points) had a risk of 21.5% of AKI-RRT.31 Mehta at al. 
used a cohort of 449 524 patients undergoing CABG, or valve surgery, or a combination 
of both, participating in The Society of Thoracic Surgeons National Cardiac Surgery 
database to develop a bedside risk algorithm for estimating patients’ probability for 
dialysis postoperatively.30 Wijeysundera et al. created a simplified renal index, which used 
only eight preoperative factors to predict dialysis after cardiac surgery.32 These predictive 
models may be valuable to plan protective strategies in high-risk patients, or to select 
patients for clinical trials. 
 
 
 
 
 
 
36 
Risk Factor Points 
Female gender 1 
Congestive heart failure 1 
Left ventricular ejection fraction <35% 1 
Preoperative use of IABP 2 
COPD 1 
Insulin-requiring diabetes 1 
Previous cardiac surgery 1 
Emergency surgery 2 
Valve surgery only 1 
CABG + valve surgery 2 
Other cardiac surgeries 2 
Preoperative creatinine 107 to <186 μmol/l 2 
Preoperative creatinine ≥186 μmol/l 5 
 
Table 4. Cleveland Clinical score to predict AKI requiring dialysis after cardiac surgery 
2.6.2. Pharmacological interventions to prevent CSA-AKI 
The multi-factorial pathophysiology of CSA-AKI and numerous discovered risk factors 
have initiated research of various preventive strategies. The main target of these 
interventions has been to improve renal blood flow or alter inflammatory reaction. 
Currently the evidence of these studies is inconsistent and there are no known drugs that 
have conclusively proved to protect kidneys in cardiac surgery.  The pharmacological 
agents used in randomized controlled studies are listed in Table 5. 
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Table 5. Agents and actions tested in randomized, controlled trials to prevent or treat CSA-AKI. 
None of the pharmacological treatments prevents the development of AKI, whereas early start of 
RRT may improve the outcome of AKI patients. NAC, N-acetylcysteine; ANP, atrial natriuretic 
peptide; BNP, brain natriuretic peptide; ACEI, Angiotensin-converting enzyme inhibitor; ARB, 
Angiotensin II receptor blocker; CRRT, continuous renal replacement therapy; RRT, Renal 
replacement therapy 
Acetylsalicylic acid (ASA) 
Patients presented to cardiac surgery are usually medicated with ASA, which has been 
proved to reduce cardiovascular events in patients with coronary artery disease. Mangano 
et al. investigated in a large cohort study of 5065 patients the impact of ASA use within 48 
hours of CABG surgery on AKI, including dialysis and death caused by renal failure.169 
ASA therapy was associated with a 74% reduction in the incidence of renal failure. In a 
recent retrospective study ASA therapy within 5 days preceding surgery significantly 
reduced the risk of 30-day mortality, postoperative renal failure, and requirement of 
dialysis.170 In a randomized, blinded, clinical trial of 6905 patients undergoing non-cardiac 
surgery the patients were assigned to take ASA or placebo 2 to 4 hours before surgery and 
then ASA or placebo daily up to 30 days after surgery, ASA did not change the risk of 
AKI, which occurred 13.4% in the ASA group and 12.3% in the placebo group, but ASA 
increased the risk of major bleeding.171  
 
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers 
(ARB) 
It is common to patients undergoing cardiac surgery to receive long-term treatment with 
ACEI or ARB. Their effect during anesthesia and surgery is difficult to predict because 
 
Anti-
inflammatory 
Natriuretics / diuretics Vasodilators Other 
NAC Nesiritide Diltiazem Albumin 
Leukodepletion ANP/BNP Dopexamine Early CRRT 
Acetylsalicylic acid Furosemide Dopamin RRT 
Dexamethasone Urodilatin Fenoldopam Insulin 
Methylprednisolone Mannitol ACEIs/ARBs Clonidine 
Sodium bicarbonate Mannitol + furosemide + 
dopamin 
Sodium nitroprusside Hydration with 0.5% 
saline 
 
NAC + fenoldopam  Theophylline  
  Nifedipine  
  Levosimendan  
  Dopamin + fenoldopam  
  Dopamin + mannitol  
  Dopamin + 
nitroprusside 
 
  Dopamin + furosemide  
  Dopamin+ 
phenylephrine 
 
  Dopamin + diltiazem  
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when they usually increase renal blood flow, during renal hypoperfusion the maintenance 
of GFR is dependent on renal angiotensin II-induced efferent arteriolar vasoconstriction, 
and thus ACE inhibition may lead to reduction in GFR.172 Some studies have 
demonstrated higher postoperative risk for AKI with preoperative use of ACEIs/ARBs, 
and discontinuing this therapy before surgery may reduce the incidence of AKI.173 Other 
studies, however, have found that preoperative ACEIs do not increase, but rather reduce, 
the incidence of postoperative AKI.174 Appropriately sized randomized controled trials are 
needed to find conclusive evidence of the perioperative use of these drugs. 
 
Dopamine, mannitol, furosemide 
Several prospective randomized clinical trials have found that dopamine has no effect on 
the prevention of AKI.175,176 Also, a meta-analysis of cardiac surgery patients revealed that 
dopamine failed to reduce the incidence of acute renal failure, need for dialysis or risk of 
death.177 In a trial of dopamine and mannitol, the excretion rates of beta2-microglobulin 
were measured in patients undergoing CABG surgery with CPB, and dopamine alone, or 
in combination with mannitol, increased the beta2-microglobulin excretion rates, which 
indicated tubular dysfunction.178  
Mannitol is an osmotic diuretic and widely used in the priming fluid for CPB. In a 
small prospective trial patients with normal renal function or with renal dysfunction were 
randomized to receive 0.5 g/kg of mannitol or an equivalent volume of Hartmann’s 
solution in the pump prime.179,180 There were no differences between the groups in plasma 
creatinine, change in creatinine from baseline, urine output, urinary retinol binding 
protein, or urinary microalbumin postoperatively. In a recent study in a treatment of CSA-
AKI mannitol infusion induced renal vasodilatation and increased renal blood flow. 
Mannitol treatment did not affect filtration fraction or renal oxygenation, suggestive of 
balanced increases in perfusion/filtration and oxygen demand/supply.181 Mannitol seems 
to be safe to use in priming fluid, but it has not demonstrated any renal protection in 
cardiac surgery. The therapeutic role of mannitol needs further studies. 
 
A double-blind randomized controlled trial evaluated the effectiveness of dopamine or 
furosemide in prevention of SCA-AKI.175 Patients with normal preoperative renal function 
received a continuous infusion of dopamine, or furosemide, or placebo from the start of 
the surgery and continuing for 48 hours. The effect of dopamine and placebo did not differ 
in preventing renal dysfunction, but furosemide was associated with the highest rate of 
renal impairment.175 Also a preoperative use of diuretics has been associated with 
increased risk of RRT in a retrospective study.182 
 
N-acetycysteine 
The formation of free oxygen radicals has been proposed to be associated with 
cardiopulmonary bypass and cardioplegic arrest, thus radical scavenging may protect 
kidney function in cardiac surgery.11 NAC is a thiol compound with antioxidant and 
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vasodilatory properties, and it has been found to reduce oxygen free radical production, 
pump-related ischemia-reperfusion injury, and pro-inflammatory cytokine levels.183-185  
Cardiac surgery patients are often exposed to contrast media during cardiac catheterization 
prior surgery, and the kidneys suffer two insults in a short time interval. NAC was first 
used to prevent contrast-induced AKI (CI-AKI), and many small studies of NAC 
administrated before the kidney insult have demonstrated a protective effect on CI-AKI.186 
However, a prospective trial in patients with renal insufficiency undergoing cardiac 
catheterization did not find difference in renal protection between the groups hydrated 
with sodium bicarbonate, or sodium chloride, or oral NAC.187 The result was the same in a 
trial where patients were hydrated with sodium bicarbonate or normal saline: NAC did not 
reduce CI-AKI in either group.188 Although the evidence of renoprotective effect of NAC 
is conflicting, in 2012 KDIGO suggest using oral NAC, together with intravenous isotonic 
crystalloids, in patients at increased risk of CI-AKI.189 
A list of randomized, controlled trials (RCT) using prophylactic administration of 
NAC to prevent postoperative CSA-AKI is seen in Table 6. Fischer et al. performed a 
retrospective review of 40 patients from the authors’ recent RCT.190 NAC was associated 
with reduced rise in serum creatinine and improved creatinine clearance after cardiac 
surgery. After that Burns et al. published a paper of adequately powered RCT of high-risk 
patients undergoing elective or urgent CABG.191 They discovered no difference in 
development of postoperative AKI in the NAC group compared to the control group, there 
were also no significant difference in postoperative interventions between the groups. 
Wijeysundera et al. investigated the effect of NAC in patients with moderate preoperative 
renal dysfunction.192 They were able to demonstrate that perioperative NAC resulted in a 
trend to reduced reduction in eGFR, but there was not a significant difference between the 
NAC group and the control group. There was no statistically significant difference in the 
need for RRT. However, there was a significant reduction (P = 0.007) in mortality in the 
NAC group, although the study was not powered for this secondary outcome. Haase et al. 
performed a RCT in 60 patients at high-risk of postoperative AKI.193 They could not find 
any difference in the absolute change in serum creatinine or peak serum creatinine, and 
writers concluded that administration of high-dose NAC is no more effective than placebo 
at decreasing AKI in high-risk patients following cardiac surgery. Sisillo et al. conducted a 
trial in 254 patients with chronic kidney disease undergoing elective cardiac surgery.194 
AKI, defined as more than 25% increase in serum creatinine, occurred in 40% of NAC-
treated patients and in 52% of control patients, but the difference was not significant (p = 
0.06). However, NAC was associated with reduction in duration of mechanical ventilation 
and length of stay in ICU. Adabag et al. carried out a RCT in 102 patients with pre-
existing renal insufficiency undergoing cardiac surgery.195 They found that NAC did not 
reduce the incidence of AKI or rise in serum creatinine. NAC also had no impact on 
requirement of RRT, mortality, and length of stay in ICU or hospital. Because of the many 
RCTs without adequate power to prove the effect of NAC in CSA-AKI, Niwekar and 
Kandula conducted a meta-analysis of twelve studies comprising 1324 patients.196 The 
authors deduced that NAC did not reduce the risk of AKI, RRT requirement, mortality, or 
length of stay in ICU. Adabag et al. performed a systematic review including ten RCTs 
with 1163 patients197. They came to the similar conclusions, NAC did not reduce the 
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incidence of postoperative CSA-AKI. Prasad et al. carried out a RCT in 70 high-risk 
patients for AKI undergoing CABG with off-pump technique.198 There was no significant 
difference in the incidence of AKI, and the writers concluded that NAC did not have any 
beneficial effect on renal function in this patient group. The latest study presents a small, 
single-center RCT of high-dose NAC in 70 patients with GFR < 60 ml/min undergoing 
CABG surgery with CPB or with OPCAB technique.199 Writers discovered a significant 
difference in the incidence of AKI between the groups. In the NAC-group the incidence of 
AKI was 29% versus 80% in the control group, although in more than 80% of patients, the 
severity of AKI was limited to Stage 1 defined with AKIN criteria. The incidence of AKI 
differed most between the patients who had CPB and did not receive NAC (63%), 
compared to patients who received NAC and had OPCAB surgery (8%). 
 
The evidence of beneficial effects of NAC on CSA-AKI is controversial, the different 
doses, administration timing and methods may influence the inconsistent results. 
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Fenoldopam 
Fenoldopam is a selective dopamine-1-agonist, which causes relaxation of smooth muscle, 
vasodilatation, and inhibition of tubular re-absorption of sodium in the kidney. It is 
considered to cause renal protection through its selective renal vasodilatory and natriuretic 
effects, and it has been associated with decreased risk of CSA-AKI in several small trials.  
Landoni et al. conducted a meta-analysis of 13 randomized and case-matched studies on 
1059 patients undergoing cardiac surgery, and they concluded that fenoldopam 
significantly decreased the requirement for RRT and decreased ICU length of stay and in-
hospital mortality.200 Later Zangrillo et al. carried out a meta-analysis of randomized, 
placebo-controled trials on 440 patients and discovered that fenoldopam significantly 
reduced the risk of CSA-AKI, odds ratio (OR) = 0.41; 95% CI 0.23-0.74; P = 0.003.201 
However, fenoldopam did not decrease the requirement for RRT or mortality. The latest 
study of fenoldopam was a multicenter, randomized, doubleblind, placebo-controlled, and 
parallel-group trial on patients with early postoperative CSA-AKI, defined as 50% 
increase of serum creatinine from the baseline or oliguria for more than six hours.202 This 
study was stopped because it was futile after a planned interim analysis. In the fenoldopam 
group 20% of patients, and in the placebo group 18% of patients received RRT. The 
mortality at 30 days was 23% in the fenoldopam group and 22% in the placebo group, and 
furthermore, there was significantly more hypotension in the fenoldopam group than in the 
placebo group. The authors concluded that given the cost, lack of effectiveness, and the 
increased incidence of hypotension, the use of fenoldopam for renal protection in cardiac 
surgery is not justified. 
 
Natriuretic peptides 
Natriuretic peptides, atrial natriuretic peptide (ANP) or B-type natriuretic peptide (BNP), 
can induce renal arterial vasodilatation, and at the same time block the renin-angiotensin-
aldosterone system and renal vasoconstrictor, endothelin, and thus increase glomerular 
filtration and also promote diuresis. A multicenter, randomized, placebo-controlled trial of 
nesiritide, human B-type natriuretic peptide, in 303 patients with left ventricular 
dysfunction undergoing cardiac surgery with CPB demonstrated that nesiritide improved 
renal function, even more in patients with preoperative renal dysfunction.203 The hospital 
stay was also shorter in the nesiritide group. The most recent meta-analysis of 15 RCTs of 
natriuretic peptides in cardiovascular surgery patients discovered that the infusion of ANP 
significantly decreased peak serum creatinine levels, the incidence of arrhythmia, and 
RRT.204 It also showed that perioperative ANP or BNP infusion significantly decreased 
both ICU and the length of hospital stay, but the data was insufficient to determine the 
long-term outcome. There are three recent trials showing beneficial effects of ANP in 
CABG surgery in three different patients populations. Patients with preoperative normal 
renal function, and patients with reduced left ventricular function, treated with ANP 
suffered less of AKI than patients in the placebo-control group, but the patients with 
preoperative renal dysfunction treated with ANP had also less RRT postoperatively.205-207 
The authors concluded, that larger, adequately powered, multicenter trials are needed to 
confirm their findings.  
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Sodium bicarbonate 
Hemoglobinuria has been associated with CSA-AKI.  Urine alkalization may protect 
kidneys from injury induced by oxidant substances, iron-mediated free radical pathways, 
complement activation, and tubular hemoglobin cast formation and hemoglobin induced 
pigment nephropathy.208 Haase et al. conducted a RCT with 100 cardiac surgery patients 
and discovered significant reduction (p < 0.043) in postoperative AKI, defined as an 
increase of 25% from baseline creatinine, and a significant decrease in urinary NGAL in 
association with the use of perioperative sodium bicarbonate infusion.209 However, the 
authors conducted a multicenter, doubleblind RCT, but they could not confirm these 
findings, as patients administrated sodium bicarbonate developed more AKI than patients 
in the control group (47.7 % vs 36.4%, OR 1.60; 95%CI 1.04-2.45).210 Also urinary 
NGAL increased more in patients receiving sodium bicarbonate infusion, the incidence of 
RTT was similar in both groups, but the hospital mortality was increased in bicarbonate 
group of patients.  According to current data sodium bicarbonate is not recommended to 
use as renal protection in cardiac surgery. 
 
Levosimendan 
Levosimendan is a calcium sensitizer that enhances myocardial contractility without 
increasing myocardial oxygen use.211 In cardiac surgery patients, an early postoperative 
infusion of levosimendan produced significant increase in renal blood flow and glomerular 
filtration rate, decreased renal vascular resistance, but did not increase renal oxygen 
consumption, or renal oxygen extraction, compared to patients in placebo group.212 
Harrison et al. conducted a meta-analysis of 1115 patients in 14 RCTs, and evaluated the 
effect of perioperative levosimendan on renal function, and found that it significantly 
reduced the need for dialysis (risk difference, RD -4.9%; 95%CI -8.2%, - 1.6%; p=0.003). 
In a smaller meta-analysis of 529 patients in 5 randomized trials the authors suggested that 
levosimendan might reduce renal injury in cardiac surgery.213 A board of experts 
published recently an evaluation of the use of levosimendan in cardiac surgery and 
concluded the favorable effects of levosimendan on renal parameters, but evidence of its 
ability to reduce CSA-AKI is still lacking.214 
2.6.3. More strategies to prevent CSA-AKI 
Preoperative anemia defined as hemoglobin less than 125 mg/l, as well as perioperative 
transfusion of red blood cells, have been identified as risks to SCA-AKI.105 The strategies 
to avoid these events may reduce the risk of renal injury. In a parallel-group randomized 
pilot study a prophylactic transfusion of red blood cells to anemic (hemoglobin 100-120 
mg/l) cardiac surgery patients reduced perioperative anemia and transfusion, but there was 
no difference between the groups in the incidence of postoperative AKI.106 However, the 
patients who received perioperative red blood cell transfusion, had higher postoperative 
transferrin saturations, which was associated with postoperative AKI. In a small pilot 
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study the administration of prophylactic erythropoietin prevented AKI and improved 
postoperative renal function.215 In a placebo controlled trial with patients undergoing 
valvular surgery, a group of anemic patients received a prophylactic dose of erythropoietin 
plus iron supplement, the treatment group had significantly less perioperative transfusion, 
and also less AKI.216 
 
In cardiac surgery studies on the relationship between optimized perioperative 
hemodynamics and postoperative renal function are lacking. In a small, randomized study 
the cardiac surgery patients with chronic kidney disease received intravenous hydration of 
0.45% saline at 1 ml/kg/hour for 12 hours before surgery versus no hydration, AKI 
developed in 53% of patients in the control group versus 30% in the hydration group (p < 
0.01).217 RRT was needed in four patients in the control group, but none in the hydration 
group. More studies are needed to confirm these results, but avoidance of hypovolemia, 
and perhaps diuretics, before cardiac surgery is associated with reduced kidney injury. 
 
The optimal time to initiate RRT in CSA-AKI is still not certain, but there is some 
evidence that early start of RRT may improve the outcome of these patients.218 In a 
retrospective, observational, multi-center study including 204 patients from 24 hospitals 
the patients were divided in two cohorts based on the time at which RRT was initiated: 
before the third postoperative day, early-RRT group, or after that, late-RRT group. The 
late RRT group had significantly higher in-hospital mortality (80.4% vs. 53.2%; p<0.001), 
longer adjusted hospital stays by 11.6 days (95% CI: 1.4-21.9), and higher adjusted 
relative increase in creatinine at discharge than the patients in early-RRT group.218 The 
KDIGO guideline on renal support therapy for AKI proposed initiating RRT without delay 
when life-threatening changes in fluid, electrolyte, and acid-base balance exist.189 The 
same guidelines suggest continuation of RRT as long as it is required, and it should be 
discontinued when intrinsic kidney function has recovered to maintain patient needs. 
Furthermore, KDIGO also recommends not to use diuretics to improve the recovery of 
kidney function or to reduce the duration or frequency of RRT.189 
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3. AIMS OF THE STUDY 
The aim of this thesis was to examine the kidney injury during and after cardiac surgery. 
The specific aims of the studies I-IV were: 
 
1. To determine if serum cystatin C can disclose mild renal failure earlier than 
creatinine in elderly patients recovering from cardiac surgery 
 
2. To study the suitability of cystatin C, NAG and creatinine in the detection of renal 
failure after cardiac transplantation 
 
3. To investigate the renoprotective effects of N-acetylcysteine in patients with mild 
preoperative renal failure undergoing cardiac surgery 
 
4. To evaluate the effects of levosimendan on post-cardiac surgical renal function in 
patients with preoperatively compromised heart function 
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4. PATIENTS AND METHODS 
4.1. Patients 
The studies I to IV were conducted at the Helsinki University Hospital between 2004 and 
2010, study IV was carried out also at Turku University Hospital. The Ethics Committee 
of Helsinki University Central Hospital approved all study protocols, and The Finnish 
National Agency of Medicines approved the Studies III and IV. Written informed consent 
was obtained from all 288 cardiac surgery patients participating in these studies. The 
design of study, number of patients, inclusion and exclusion criteria, aims, and kidney 
laboratory measurements are listed in Table 4. The demographic data of the patients are 
presented in Table 7. 
 
Variables (n) Study I Study II Study III Study IV 
Number of patients 110 41 77 60 
Age 77  52  70  64 
Gender (male) 60 (54%) 23 (56%) 62 (80%) 54 (90%) 
BMI  24 28 28 
ACE/AT2  37 (90%) 51 (66%) 34 (57%) 
Statins * 15 (37%)  * 39 (65%) 
LVEF     
  >50% 81 (74%)   0 36 (47%) 0 
50 to 35 % 23 (21%) 0  15 (19%) 15 (25%) 
< 35% 6 (5%) 41 (100%) 26 (34%) 45 (75%) 
Diabetes 29 (26%) 2 (5%) 28 (36%)  23 (38%) 
Peripheral vascular disease 19 (17%) 10 (24%) 15 (19%) * 
CABG 34 (31%) 0 38 (49%) 60 (100%) 
Valve 44 (40%) 0 13 (17%) 0 
CABG + valve 32 (29%) 0 26 (34%) 0 
Heart transplantation 0 41 (100%) 0 0 
 
Table 7. Demographic data of Studies I – IV 
*Not assessed in the study 
Data are presented as median or number (%) 
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4.2 Study design 
Study I 
In study I we tested whether serum cystatin C is able to detect AKI earlier than plasma 
creatinine after cardiac surgery with elderly patients.  The blood samples for plasma 
creatinine and serum Cystatin C were collected before surgery in the operation room as a 
baseline, and on the days 1 to 5 thereafter, the samples were analyzed immediately after 
they were collected. The patients with AKI were categorized to three different groups 
based on the changes in plasma creatinine, urine output, or eGFR according to the RIFLE 
criteria. In the morning of the operation the patients received their routine cardiac 
medication excluding ACEIs or ARBs. The attending anesthesiologist decided the 
administration of aprotinin or tranexamic acid, otherwise the anesthesia and CPB 
management followed the standardized protocol. GFR was calculated with the MDRD 
equation. We also assessed hemodynamic data, medication with vasoactive drugs, 
diuretics, transfusions, and fluid balance. Table 8 lists study designs I-IV. 
 
Study II  
The primary aim of the study II was to find out whether cystatin C increases before 
creatinine in heart transplant patients with postoperative AKI. Preoperative renal function 
was determined with 51Cr-EDTA-GFR (35 patients) or calculated with the MDRD 
equation (6 patients). The baseline blood samples for plasma creatinine and serum cystatin 
C were collected a few hours before the heart transplantation, 24 hours after the beginning 
of the operation, and on days 1 to 5 postoperatively. In addition, the urine samples for 
NAG and creatinine were obtained in the beginning of the transplantation, at the end of the 
surgery, and on days 1 to 3 postoperatively. We used RIFLE criteria to identify the 
patients with AKI. The information of administrated vasoactive medication, hemodynamic 
values and calculations, administrated fluids, and blood products were collected from a 
computerized data collection. 
 
 Study III 
We evaluated the effect of N-acetylcysteine (NAC) in patients with preoperative renal 
dysfunction. The kidney function was measured with plasma creatinine, serum cystatin C, 
and urine NAG. Eighty patients scheduled to elective CABG with CPB were randomized 
to receive NAC (Group NAC), or placebo (Group Placebo). One patient in the NAC-group 
was excluded from analysis due to protocol violation, and with one patient in NAC-group 
and one in placebo-group operation was inverted to off-pump coronary artery bypass. 
Before the induction of the anesthesia NAC (Parvolex®, Celltech Pharmaceuticals Ltd, 
Slough, UK), prepared in saline 0.9%, was administrated as a loading dose of 150 mg/kg 
in 15 minutes, followed by 50 mg/kg for next 4 hours, and thereafter, 100 mg/kg for 16 
hours. The placebo group was given similar volumes of saline 0.9%. The hospital 
pharmacy carried out the randomization and prepared study medications. The anesthesia 
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and CPB were performed according to a standard protocol, none of the patients received 
aprotinin.  
 
The urine and blood baseline samples were collected before the study drug was started. 
The other urine samples were collected from the urine excreted between following time-
points: from the insertion of the urinary catheter to the start of CPB, from the beginning of 
CPB until the end of surgery, first 6 hours after surgery, from 6 to 12 hours after surgery, 
and the last on the fifth day after operation. To avoid the effect of variations in the 
concentration of urine we calculated urine creatinine and NAG ratio by dividing the value 
of NAG (unit/l) with that of creatinine (μmol/l). The other blood samples for creatinine 
and cystatin C were obtained in the morning of the first, third, and fifth day 
postoperatively. 
 
The primary outcome measure was an increase in urine NAG/creatinine ratio at 30% 
above baseline. The changes of plasma creatinine and serum cystatin C were also 
analyzed. Postoperative renal dysfunction was defined as an increase of plasma creatinine 
from baseline over 25%, or more than 44μmol/l, or an increase of serum cystatin C level 
above 1.4 mg/l. We also assessed 30-day mortality, need for RRT, length of ICU stay, and 
possible side effects of NAC. 
 
Study IV  
The study was performed in two centers, 42 patients were treated in center one and 18 
patients in center two. Demographic data are shown in Table 5, no differences were found 
between the groups. The aim was to assess the effect of levosimendan on postoperative 
renal function in patients with impaired left ventricular function undergoing CABG 
surgery with CPB. This study was performed with the same patients as a previous study 
evaluating levosimendan for weaning patients from CPB, and the power of study was also 
calculated for that purpose.219 Sixty patients were randomized to receive levosimendan or 
placebo infusion. After the first hemodynamic measurements using a pulmonary artery 
catheter, study drug infusion was administrated as a bolus dose of 12 μg/kg of 
levosimendan in 10 minutes, followed by a continuous infusion of 0.2 μg/kg/min for a 
total infusion period of 24 hours. The kidney function was evaluated with plasma 
creatinine, serum cystatin C, and urine NAG. GFR was calculated with MDRD equation. 
Plasma creatinine and serum cystatin C samples were collected at the baseline before 
surgery, at 6 and 24 hours after de-clamping of the aorta, and on the second and fifth 
postoperative day. Urine NAG was analyzed at the baseline, and at 6 hours and 24 hours 
after de-clamping of the aorta. AKI was determined with RIFLE criteria. 
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4.3. Anesthesia and CPB management 
Anesthesia was induced with intravenous propofol or etomidate and sufentanil and 
maintained with inhaled sevoflurane and continuous infusion of sufentanil. Muscle 
relaxation was provided by rocuronium. During the induction of anesthesia MAP of 60 to 
70 or higher was maintained with boluses of phenylephrine and Ringer’s solution when 
needed. The filling pressure of left ventricle was maintained at the base level or at he 
pulmonary capillary wedge pressure (PCWP) of 10 to 12 mmHg. The cardiac performance 
and valve dysfunctions were evaluated with transesophageal echocardiography (TEE). 
CPB was performed using nonpulsatile flow of 2.4 l /min/m2, a hollow-fiber 
membrane oxygenator, and arterial filter. The perfusion circuit was primed with Ringer’s 
acetate and 100 ml of from 6% to 15% mannitol, depending on the study protocol. During 
the perfusion, the mean arterial pressure was maintained between 50 and 90 mmHg, the 
hematocrit above 22%, and mixed venous saturation above 70%. Myocardial protection 
was achieved with intermittent, cold crystalloid cardioplegia with blood in ratio of 4:1 or 
8:1, except in heart transplantation where we used cold crystalloid cardioplegia. During 
CPB the patients were allowed to cool passively to 30°C to 32°C, and rewarmed to 36°C 
before weaning from CPB. During CPB mediastinal suction blood was returned to the 
venous reservoir, and after the patients were withdrawn from CPB, the content of the 
circuit was collected and returned to the patients.  
 
After CPB cardiac function was evaluated with TEE and cardiac index was measured 
with a pulmonary artery catheter, the intended goal was above 2.0 l/min/m2. If the cardiac 
index was below the threshold, and pulmonary wedge pressure was maintained at least 10 
mmHg, epinephrine infusion was started, and milrinone infusion was added for further 
support. MAP was maintained above 70 mmHg, and norepinephrine infusion was 
administrated when needed. In severe low- output syndrome, or when the patients could 
not be weaned from CPB, IABP or LVAD was installed. In heart transplantation the right 
ventricle dysfunction was treated with nitric oxide. In the ICU the sedation was provided 
with propofol, until the patients were weaned from the respirator according to the routine 
guidelines. 
4.4. Laboratory analysis 
All laboratory samples were analyzed at the HUSLAB, Helsinki University Hospital. 
Serum cystatin C samples were analyzed with the particle-enhanced immunoturbidimetric 
assay (Dako Cytomation, Glostrup, Denmark A/S), the reference value of normal limit 
was 1.2 mg/l. Plasma and urine creatinine were analyzed with the enzymatic assay method 
(Roche Diagnostics GmbH, Mannheim, Germany) and on a Hitachi Modular analyzer, the 
reference value of plasma creatinine above normal limit being 95 μmol/l. Urine NAG was 
measured with the colorimetric assay (Roche Diagnostics GmbH). In study III plasma and 
urine samples were stored at - 20°C and analyzed later. In this study the within-series 
coefficient of variation to NAG was 2.1 and 3% at 8.9 and 4.7 U/liter, respectively, and 
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the between–series coefficient of variation was 5.2% at 8.0 U/liter. In other studies all 
laboratory parameters were analyzed after the collection with the standard procedures of 
HUSLAB. 
 
Definition of AKI 
In Studies I, II, and IV we defined AKI with the increase of plasma creatinine, and urine 
output according to the RIFLE-criteria.21 AKI was determined during the first 5 
postoperative days and the patients with kidney injury were categorized to the following 
groups: (i), Risk, if plasma creatinine increased by 1.5 fold, or GFR decreased over 25%, 
or urine output was less than 0.5 mg/kg/h for more than six hours; (ii), Injury, if plasma 
creatinine increased by 2.0 fold, or GFR decreased over 50%, or urine output was less than 
0.5 mg/kg/h for more than 12 hours; (iii) Failure, if plasma creatinine increased by 3.0 
fold, or GFR decreased over 75 %, or plasma creatinine was above 356.6 μmol/l with 
acute increase of more than 44.2  μmol/l, or RTT was administrated, or urine output was 
less than 0.3 ml/kg/h for 12 hours, or anuria for more than 12 hours. 
We used plasma creatinine to calculate the estimated GFR. GFR was with MDRD: GFR 
(ml/min/1.73m2) = 186 x Cr(-1.154) x Age(-0.203) x (0.742 for females).115  
4.5. Monitoring and data collection 
All the patients were continuously monitored using a standard protocol; 
electrocardiography, peripheral capillary oxygen saturation, nasopharyngeal and bladder 
temperature, and neuromuscular block and bispectral index monitoring during anesthesia. 
A radial artery cannula was inserted for arterial pressure recording and blood sampling. 
After induction of anesthesia a pulmonary artery catheter was introduced for monitoring of 
hemodynamic variables, and for continuous recording of mixed venous oxygen saturation 
(SvO2). During anesthesia TEE was performed at he beginning of the anesthesia and 
thereafter whenever needed. The continuously measured hemodynamic data, heart rate, 
MAP, central venous pressure (CVP), mean pulmonary artery pressure, and SvO2, were 
collected from the clinical data management system (PICIS, Wakefield, MA, USA). The 
regular manual measurements of cardiac index and PCPW were also recorded to PICIS.  
Clinical data included also administration of inotropes, vasopressors, fluids, blood 
products, and hourly urine output, blood loss, fluid balance, and routine blood sample 
parameters. 
4.6. Statistical methods 
The statistical analyses in studies I-IV were performed using statistical software (SPSS 
package, versions 11.5, 13.0, 19.0; Chicago, IL and Analyse-it software Ltd; Leeds; UK).  
In studies I to IV, the patient data are reported as absolute numbers and percentages, as 
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median values with interquartile ranges (IQR, 25th and 75th percentiles), or as means and 
standard deviations (SD). A p-value <0.05 was considered statistically significant in all 
studies. 
 
In study III the sample size was calculated as 40 patients per group to have 80% power 
in detecting a significant  (30%) difference in the levels of NAG at 95% CI limits (α = 
0.05). In the study IV the power was calculated for the primary outcome measure, the 
effect of levosimendan in weaning patients with heart dysfunction from CPB.219 
 
In studies I and II we compared the groups using the Mann-Whitney U test or 
independent samples t test and categorical variables using the χ2 -test, followed by Fisher 
exact test when appropriate. The changes in kidney laboratory measurements between the 
groups were performed with repeated measures analysis of variance (ANOVA). Same 
method was used to compare the proportional changes of creatinine and cystatin C values 
in AKI and None-AKI patients groups, with values over the time (five time points) as 
within factors, the marker (creatinine or cystatin C) as the between factors, and the 
interactions of these two markers over time. The appropriate F value as a measure of 
variance and p values for testing for statistical significance of the factors were calculated. 
In Study II to demonstrate the discriminative ability of creatinine and cystatin C to predict 
postoperative AKI at different time points we used receiver operating characteristics 
(ROC) curves with the respective areas under the curve (AUC). The studied time points 
were before surgery, and on the first and second postoperative days. The ROC curves and 
the AUC values were compared with a nonparametric method. 
 
In studies III and IV comparison between the groups were performed with the 
independent samples t-test for continuous variables, and for categorical data the χ2 -test, 
followed by Fisher exact test when appropriate, The continuous variables were compared 
using a repeated measures analysis of variance model with effects for treatment, time 
point, and treatment-time point interaction. They were also evaluated separately at each 
time point by treatment using ANOVA. 
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5. RESULTS 
5.1. Ability of cystatin C to detect postoperative acute kidney 
injury in elderly cardiac surgery patients (I) 
The incidence of AKI was 56.4% according to RIFLE criteria. Sixty-two patients out of 
110 suffered AKI: 48 patients had a Risk, 12 patients belong to Injury group, and 1 patient 
had renal Failure. The number of patients in the AKI group with > 50% increase of the 
plasma creatinine and serum cystatin C in studies I and II are presented in Table 9. The 
median and interquartile range (IQR) values of plasma creatinine and serum cystatin C in 
studies I and II are presented in Table 10. The ANOVA analysis indicated that in the AKI 
group the proportional change of serum cystatin C and plasma creatinine was significant 
over time, but the changes occurred in a similar way. The concentration of the both 
markers peaked on third postoperative day. The ROC curves for the absolute values of 
creatinine and cystatin C demonstrated equal correlation with AKI at different time points. 
On postoperative day 1 the AUC for creatinine was 0.66 (0.55-0.76) and for cystatin C 
0.71 (0.61-0.81), p = 0.11, and on postoperative day 2 the AUC for creatinine was 0.74 
(0.64-0.83) and for cystatin C 0.77 (0.68-0.86), p = 0.32.  
 
There were no differences between the patients with AKI and without AKI in 
hemodynamic measurements, use of inotropes and diuretics, fluid balance, blood loss, and 
red blood cell transfusions. One patient required RRT during the study period. Four 
patients needed IABP postoperatively, one of them was the patient receiving RRT. The 
30-day mortality was 2.7%. 
5.2. AKI after heart transplantation, the roles of NAG, cystatin C, 
and creatinine (II) 
AKI occurred in 23 out of 41 patients (56%) after heart transplantation. Using RIFLE 
criteria patients with AKI were categorized to three groups: Risk included 5 patients, 
Injury 4 patients, and Failure 14 patients. In the AKI-patients serum cystatin C and plasma 
creatinine increased significantly compared to patients without AKI, both plasma 
creatinine and serum cystatin C peaked on postoperative day 5 at the end of the study 
period. Preoperatively 17 (41 %) patients had creatinine and cystatin C above normal 
limits. On day one creatinine increased over 25 % in 15 (36.6%) patients, 7 of these 
patients had increased preoperative values. On day one cystatin C increased over 25 % in 
12 (29.3%) patients, but only 2 of those patients had preoperative cystatin C value above 
the normal limits. In the patients without AKI these markers behaved differently, as 
creatinine decreased from the baseline on postoperative days 1 to 5, but cystatin C first 
decreased on postoperative day one and increased thereafter. Urine NAG/creatinine ratio 
increased significantly in both AKI and non-AKI patients groups at the end of the surgery, 
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but there was no significant difference between the groups. The values returned close to 
baseline on postoperative day 1 and remained low in the rest of the measurements.  The 
proportional changes of creatinine and cystatin C were compared with repeated measures 
of ANOVA, which demonstrated that, in patients with AKI, both markers increased 
significantly over the time (p < 0.001). There was a significant difference between the two 
markers, but the interaction over time was not significant, thus the changes of the markers 
occurred in a similar way over the period of time. In patients without AKI, the 
proportional changes of plasma creatinine and serum cystatin C performed differently, 
cystatin C increased 38% from the baseline and creatinine decreased 7% during the study 
period (p < 0,001). 
 
The patients in the AKI group, had significantly more previous heart surgery 
(p=0.011), they had more more blood loss (p=0.036), they received more red blood cell 
transfusions (p=0.040), they were administrated more diuretics (p=0.019), and their urine 
output was less (p=0.005) compared to patients without kidney injury. They also received 
more nitric oxide treatment (52% vs. 22%, p=0.05) and the length of stay in ICU was 
significantly longer (p<0.001). Thirteen (31%) patients required RTT, but after one year 
after transplantation only one patient remained in dialysis.  Four patients were placed on 
extra-corporeal membrane oxygenation after the transplant surgery due to primary graft 
dysfunction; two patients recovered, one patient was re-transplanted, and one patient died. 
 
 
Table 9. The number (%) of patients with > 50% increase of plasma creatinine or serum cystatin 
C on days 1 to 3 postoperative day. 
 
 
 
 
 
 
 
 
 
 
 
 
 Plasma creatinine Serum cystatin C 
 Study I  n=110 Study II n=41 Study I  n=110 Study II  n=41 
Patients 30  21  17 19 
Day 1 7 (23) 8 (38) 3 (18) 7 (37) 
Day 2 8 (27) 7 (33) 9 (53) 7 (37) 
Day 3 15 (50) 6 (29) 5 (29) 5 (26) 
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Table 10. Median and Interquartile Range Values of plasma creatinine and serum cystatin C 
before surgery and postoperative days 1 to 3 in Studies I and II 
5.3. Effect of N-acetylcysteine on kidney function in cardiac 
surgery patients with chronic kidney disease (III) 
At the base level there was no significant difference in the mean (SD) plasma creatinine, 
which was 127 (26) µmol/l in the N-acetylcysteine (NAC) group and 134 (45) µmol/l in 
the placebo group (p=0.376). According to the definition of AKI, 35 (45%) patients had 
postoperative AKI; 16 (42%) in the NAC group, and 19 (49%) in the placebo group.  The 
U-NAG/creatinine ratios did not differ between the study groups. Furthermore, there was 
no significant difference in plasma creatinine and serum cystatine C values between the 
groups during the five day study period.  The patients in the NAC group received 
significantly more fluids (p=0.009), had more blood loss (p=0.018), and they also had 
significantly more diuresis (p=0.045) compared to the patients in the placebo group during 
the first 24 hours after surgery. Three patients, one patient in the NAC group and two 
patients in the placebo group, died during the 30-day period after surgery. 
5.4. Effect of perioperative levosimendan on renal function in 
coronary artery surgery patients with compromised heart 
function (IV) 
Sixty patients with reduced left ventricle function were randomized to have levosimendan 
or placebo for 24 hours starting after the induction of anesthesia. In the levosimendan 
group and in the placebo group the mean (SD) baseline values of creatinine were 72.9 
(15.9) µmol/l and 71.8 (23.9) µmol/l, respectively, p > 0.05. During the five-day period 13 
(43.3%) patients developed AKI in the placebo group and 8 (26.6%) patients in the 
levosimendan group (p = 0.167). There were no significant differences between the renal 
markers plasma creatinine, serum cystatin C, and urine NAG, between the groups at any 
measurement point during the study period.  
 
 AKI patients None AKI patients 
 Study I Study II Study I Study II 
Creatinine μmo/l Day 0 72 (61-92) 106 (74-1389) 72 (60-85) 94 (62-116) 
                            Day 1 88 (64-110) 114 (90-167) 69 (60-85) 79 (64-106) 
                            Day 2 106 (77-122) 152 (115-214) 73 (64-89) 76 (59-106) 
                            Day 3 105 (80-135) 161 (119-227) 71 (62-93) 75 (59-114) 
     
Cystatin C mg/l   Day 0 1.04 (0.86-1.27) 1.41 (1.02-1.64) 0.99 (0.83-1.08) 1.25 (0.79-1.54) 
                            Day 1 1.10 (0.87-1.45) 1.48 (1.02-1.67) 0.89 (0.75-1.01) 0.99 (0.86-1.34) 
                            Day 2 1.30 (1.09-1.69) 1.89 (1.42-2.14) 0.99 (0.90-1.17) 1.04 (0.97-1.53) 
                            Day 3 1.38 (1.11-1.65) 2.17 (1.81-2.92) 1.02 (0.93-1.08) 1.20 (1.05-1.82) 
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During surgery the patients in levosimendan group required more phenylephrine 
boluses than patients in the placebo group, but in ICU there were no significant 
differences in the doses of norepinephrine between the groups. After they were weaned 
from the CPB four patients in the placebo group needed IABP compared to none in the 
levosimendan group. During the study period two patients died, both were in the placebo 
group. Figure 3. presents the changes of plasma creatinine, serum cystatin C, and U-NAG 
in the NAC-group, in the levosimendan group, and in the placebo groups in studies III and 
IV. 
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6. DISCUSSION 
6.1. Measurement of acute kidney injury and renal function (I-IV) 
Studies I and II demonstrated that cystatin C could not detect AKI before serum creatinine 
in elderly patients undergoing cardiac surgery or in patients after heart transplantation. 
 Serum creatinine has remained the benchmark measurement of renal function in spite of 
the following limitations; it has poor sensitivity and specificity, delayed change in 
concentration levels, and interference by age and body mass.118 Cystatin C has challenged 
creatinine as a marker of renal function, especially in population at risk or with chronic 
kidney disease. According to meta-analysis of 16 studies with subject population of adults 
and children and healthy volunteers and patients with varying degrees of renal dysfunction 
by different conditions, cystatin C demonstrated better correlation coefficients (0.82 vs. 
0.74, p < 0.001) and greater AUROC values (0.93 vs. 0.84, p < 0.001) with GFR than 
serum creatinine.128 However, in setting of AKI in ICU or after cardiac surgery the results 
have been inconclusive.  
 
In a meta-analysis of 13 studies including patients after cardiac surgery, pediatric 
patients, and critically ill patients AUROC of serum cystatin C to predict AKI was 0.96 
(95% CI, 0.95-0.97), but the AUROC of urinary cystatin C excretion was only 0.64 (95% 
CI, 0.62-0.66).220 A subgroup analysis of this study showed that serum cystatin C was of 
diagnostic value when measured early, as within 24 hours after the renal insult. Two 
smaller studies in cardiac surgery patients have found cystatin C to predict postoperative 
AKI similarly or slightly better than serum creatinine, and cystatin C also correlated with 
the duration and severity of AKI.141,145 Both studies discovered, that preoperative serum 
cystatin C was elevated in the patients who developed postoperative AKI, although serum 
creatinine could not detect decreased GFR in these patients. However, in large, multi-
center cohort studies, both serum and urine cystatin C, could not predict postoperative 
AKI better than serum creatinine.143,144 With high-risk cardiac surgery patients there was 
not a significant difference between the general clinical outcomes between the AKI 
patients detected by serum creatinine or cystatin C. However, the patients with AKI 
confirmed with both markers had a significantly higher risk of RRT or morbidity than the 
patients with AKI detected by creatinine alone (p = 0.002).144 
 
Additionally, timing of cystatin C measurements seems to play an important role in its 
sensitivity to detect decreased GFR.13 Haase-Fielitz et al. compared cystatin C and NGAL 
with creatinine and urea to find out if the novel biomarkers were more sensitive to predict 
AKI after cardiac surgery, and they discovered that both cystatin C and NGAL had good 
predictive value on the arrival in ICU, while creatinine and urea had poor predictive value 
analyzed with AUROC.146 After 24 hours from surgery this difference had disappeared 
and all the markers had similar predictive values. Spahillari et al. measured cystatin C 
shortly after the patient’s arrival in ICU and found it less sensitive to detect AKI. In 
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studies I and II the first postoperative renal marker measurements were performed early in 
the morning on day one, which is in the time range less than 24 hours after the surgery. 
However, this sort of delay in measurements after the putative kidney damage during 
surgery may have affected our results, although according to the results of meta-analysis 
of cystatin C in AKI, our measurements were within the time limit for cystatin C to have 
the predictive value to detect AKI.220 
 
It has been suggested that the postoperative increase in cystatin C may reflect the 
preoperative mild renal impairment more than acute change in GFR.146 In study I the 
population were elderly, thus they had presumable decline in renal function. In this study, 
preoperatively all the median values of creatinine, cystatin C, and eGFR were within 
normal limits in patients with postoperative AKI, and did not differ form the values in 
patients without postoperative AKI. In study II, preoperatively above of the normal 
cystatin C values did not carry over postoperatively in as many patients as creatinine 
values did, although in this study other factors, as steroids, might have influenced the 
cystatin C values. 
 
Cystatin C is considered to be influenced less by extra renal factors compared to 
creatinine. However, factors such as age, systemic inflammation, and use of 
corticosteroids have been proven to have an effect on serum cystatin C concentration.13 
Especially the influence of the administration of corticosteroids to cystatin C levels is 
controversial. Herget-Rosenthal et al. discovered no effect of corticosteroids on cystatin C 
with critically ill patients, but high dose steroids have been shown to increase the cystatin 
C levels with renal transplant patients.135,221 In study I the administration of corticosteroid 
did not affect cystatin C values, although the doses of hydrocortisone were less than 200 
mg per day, and were given only to the patients with preoperative use of steroids. In study 
II all the patients received immunosuppressive therapy, thus the doses were notably larger. 
On postoperative day one the proportional increase of creatinine was more (32.5 %) than 
the proportional increase of cystatin C (18.5 %) in patients with AKI, while with patients 
without AKI creatinine decreased below the baseline and cystatin C increased above the 
baseline, this change carried over the study period.  Although the effect of steroids could 
not be disregarded, there was no systematic influence of them on cystatin C concentrations 
in study II. 
 
Cystatin C is considered an unreliable marker of GFR during RRT, because its 
elimination depends on dialysis dose, volume, the type of membrane, and ultrafiltration 
rate used in RRT, and thus the reduction ratio might vary.222 In study II 56 % of AKI 
patients received RRT, the median starting day being postoperative day two. This may 
well explain why cystatin C increased more than creatinine on day four and five in 
patients with AKI. However, same trend appeared in patients without AKI, the 
proportional increase of cystatin C from the baseline being more than 30 % from the 
baseline on day three and four while creatinine levels remained below the baseline in this 
group demonstrating different behavior of these markers with heart transplant patients. 
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In cardiac surgery serum cystatin C predicts AKI similarly as plasma creatinine. In 
high-risk patients cystatin C may produce additional information, but based on published 
data it cannot replace creatinine, or be used as a sole marker of GFR. In heart transplant 
patients cystatin C seems to be a less reliable marker of AKI than creatinine, and thus 
cannot be recommended for routine use. 
 
Urine N-acetyl-β-glucosaminidase was measured as an indicator of tubular injury in 
studies II, III, and IV.  Increased U-NAG levels have been reported in several different 
chronic and acute settings of AKI, including with critically ill patients and following 
cardiopulmonary bypass.51 Katagiri et al. combined urinary NAG and L-FAB, and 
presented that together these markers detected AKI adequately after cardiac surgery 
(AUROC 0.81).223 In our studies U-NAG levels increased at the end of surgery returning 
quickly close to base level. The increase of U-NAG levels occurred in patients with and 
without AKI. There was no significant difference between the groups in which the patients 
had been treated with NAC, levosimendan, or placebo. U-NAG may be a sensitive marker 
of tubular function, but it could not predict which of the patients would develop 
postoperative AKI. Researchers have combined different markers to attain better 
diagnostic accuracy, as one marker generally reflects one putative pathophysiological 
mechanism of AKI. ADQI published a workgroup statement in 2013 and referred novel 
biomarkers, urine and plasma NGAL and urine IL-18, to be used together with clinical 
evaluation and serum creatinine to diagnose AKI after cardiac surgery.14  
6.2. Effects of N-acetylcysteine and levosimendan on renal 
function in patients undergoing cardiac surgery 
In study III N-acetylcysteine had no protective effect on renal function in cardiac surgery 
in patients with preoperative CKD. Our results are in concordance with the majority of 
evidence accumulated in this subject. 
 
In cardiopulmonary bypass NAC has attenuated reactive oxygen species, which may 
have mediated myocardial stress, and reduced ischemia–reperfusion injury.184,185 NAC has 
been proven to ameliorate kidney injury in rats following a CPB-model.224 However, 
while administrated before or during cardiac surgery NAC has not improved any 
outcomes. Six meta-analyses and systematic reviews publish between 2008 and 2011 
concluded that NAC has no effect on renal function in cardiac surgery.196,197,225-228 Wang 
et al. conducted a meta-analysis which included 1407 patients from 15 randomized trials, 
and writers could not detect differences in the incidence of over 25 % increase in serum 
creatinine above the baseline (OR = 0.86; 95% CI, 0.66-1.12; p=0.26) or need for RRT 
(OR = 1.05; 95% CI, 0.52-2.11, p = 0.90) in patients treated with NAC compared to the 
patients receiving placebo.228 They could not find a significant difference in mortality, 
new onset of atrial fibrillation, acute myocardial infarction, or stroke between the NAC 
and placebo treated patients, either. Wijeysundera et al. performed a post-hoc analysis of 
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their randomized trial of 177 patients with preoperative renal insufficiency undergoing 
cardiac surgery, and discovered that NAC was associated with increased blood loss and 
blood product transfusion.229 Naughton et al. had a similar finding in their meta-analysis, 
there was a small, but statistically significant increase in postoperative blood loss among 
patients treated with NAC. However, in a recent meta-analysis there was no difference in 
red blood cell transfusion requirements, re-exploration or postoperative drainage.225,228  
 
Although the results of the single RCT studies on NAC are inconclusive, also the 
meta-analyses have similar conclusions.  However, they have the limitations and strengths 
of the included trials. The limitations include heterogeneity of study populations, different 
definitions of AKI, different doses and administration routes of NAC, and different 
appraisal of preoperative renal dysfunction of the patients. The dose and the route of 
administration of NAC may conflict the results, because the antioxidant and anti-
inflammatory effects of NAC are related to the dose.230 
 
The pathophysiology of CSA-AKI involves multiple factors. Interestingly, there is 
experimental evidence from a few small studies to indicate, that NAC may protect kidneys 
by reducing oxidative stress, reperfusion injury, and systemic inflammatory response 
associated with cardiac surgery.184,185,224 Metabolic factors, neurohumoral activation, and 
endogenous and exogenous toxins also contribute to the development of CSA-AKI. 
Moreover, the lack of evidence on the positive effect of NAC treatment as an anti-oxidant 
in diseases characterized with increased oxidative stress indicates our lack of knowledge 
of the role of reactive oxygen species in pathophysiology of disease.231,232 
 
Low cardiac output syndrome is an extremely harmful event in cardiac surgery leading 
frequently to serious complications.233 Moreover, the therapy of low output syndrome is 
the administration of inotropes, which has been found to be associated with increased 
mortality and postoperative morbidity.234 Hypoperfusion may trigger a 
sympathoadrenergic response, hyperglycemia, and inflammation resulting in a cardiorenal 
syndrome, which can be part of CSA-AKI.235 The exception is levosimendan, and its 
administration has spread to cardiac surgery during last decade. Levosimendan is 
characterized by triple mechanism of action; it acts via calcium-dependent binding to 
cardiac troponin C, and opens the KATP channels on smooth muscle cells in the 
vasculature, and in cardiac mitochondria, and this results in its inotorpic and vasodilatory 
effects, respectively.236 The opening of KATP channels in cardiac mitochondria is believed 
to cause the cardioprotective effects of levosimendan.237 In pigs levosimendan protected 
kidney against ischemia/reperfusion injury through antioxidant and NO-related 
mechanisms.238 Harrison et al. conducted a meta-analysis to evaluate the effects of 
levosimendan in cardiac surgery patients with and without preoperative systolic 
dysfunction and discovered that mortality, postoperative AKI requiring RRT, new atrial 
fibrillation, and acute myocardial injury were reduced, especially in patients with low 
ejection fraction of the left ventricle.239 Beneficial effects of levosimendan in the weaning 
from CPB were clearly shown in the main report of the current study IV, too.219 Although 
there was no significant difference in the renal markers between the levosimendan group 
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and placebo group, there was a tendency towards preserved renal function in 
levosimendan group. Eight out of 30 patients (26.6%) had over 25 % postoperative 
increase in serum creatinine in patients treated with levosimendan, when 13 out of 30 
patients (43.3 %) had this finding in placebo group. Niu et al. conducted a meta-analysis 
of five trials with 529 cardiac surgery patients and discovered that the use of levosimendan 
was associated with lower AKI incidence 9.5 % vs. 19.2 % in the control group, OR = 
0.44 (0.22-0.85), p = 0.02.213 The role of levosimendan regarding renal function in cardiac 
surgery is not yet determined, and adequately powered, randomized trials are needed to 
prove the beneficial effects. 
 
Prevention of AKI in cardiac surgery 
There are no known drugs to prevent CSA-AKI at the present time.  There may be several 
reasons for the variable efficacy of the pharmacological interventions.240 Such as the small 
number of patients enrolled to the trials to significantly prove the effect of the studied 
drug. The studied patients are often at low risk of renal dysfunction to benefit from the 
therapy. The pathophysiology of CSA-AKI is complex and multi-factorial, thus focusing 
on one or two pathways may be insufficient to produce results. The measurement of renal 
function with creatinine may hide smaller benefits of the drug, and when creatinine level 
increases, patients may have already lost 50 % of kidney function. Currently known 
interventions to reduce the risk of CSA-AKI are to identify the patients at risk for AKI, 
avoid known nephrotoxic treatments, optimize hydration, avoid hemodilution and anemia, 
postpone surgery at least 24 hours after coronary angiography, shorten or avoid CPB, start 
statin therapy when feasible, and start RRT as soon as possible when needed. 
6.3. Limitations of studies I-IV 
Studies I and II were single center cohort studies with limited study population.  They 
were also underpowered to detect the relationship between creatinine and cystatin C and 
severe renal failure requiring RRT or morbidity. The absolute changes in creatinine and 
cystatin C do not reveal the superiority of the other marker without the hard outcomes as 
RRT or morbidity, and that requires large multicenter cohorts.  
Study III was statistically powered to detect the positive effect of NAC on tubular 
function. NAG values increased in both study groups indicating the change in tubular 
function after CBP, but in later studies NAG alone has not proved to be a very reliable 
marker of the kidney damage in cardiac surgery.241 The study population should have been 
larger to insure assessing AKI with substantial increase of creatinine or need for RRT. 
Another limitation was the different types of cardiac surgeries increasing the heterogeneity 
of the study patients. However, the inclusion criterion of increased preoperative creatinine 
made the study population more homogenous compared to the studies carried out with 
high-risk patients without knowledge of the accurate preoperative renal function. 
The limitation of study IV was its small size. It was a sub-study study to detect both 
positive and negative renal effects of a novel drug, levosimendan. It was not powered to 
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demonstrate its ability to reduce AKI after CABG surgery, but as a new inotrope it was 
associated with slight tendency to reduce kidney injury without harmful effects. 
6.4. Future prospects 
Due to the complex pathogenesis of CSA-AKI, it is unlikely that it can be influenced with 
only one intervention. The prevention of AKI requires multi-factorial approach where the 
co-morbidities of the patient and the specific characteristics of cardiac surgery are taken 
into consideration. Early recognition of AKI is required for timely intervention. Although 
NGAL and IL-18 may improve the detection of developing CSA-AKI, even more accurate 
diagnostic tools are needed. In a recent study regional renal oximetry was applied to the 
patients undergoing cardiac surgery with CPB.242 The investigators discovered that 
patients who developed CSA-AKI appeared to have longer duration of low regional renal 
oxygenation, however, the treatment to this hypoperfusion is still not answered. The 
research of the pathophysiology of AKI may result in new treatments. Mitochondrial 
injury appears to be an early pathogenic event in multiple forms of AKI, and the treatment 
and prevention of kidney insult may include preventing mitochondrial injury, stimulating 
clearance of injured mitochondria, and mitochondrial biogenesis, thus a mitochondrial-
based drug may ameliorate also CSA-AKI.243 
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7. CONCLUSIONS 
The following conclusions can be made from the presented data: 
 
1. Serum cystatin C and plasma creatinine detected AKI in a similar way after cardiac 
surgery with elderly patients. Serum cystatin C did not improve the detection of 
AKI. 
 
2. Serum cystatin C and plasma creatinine changed similarly in patients with AKI 
after heart transplantation. Serum cystatin C increased postoperatively with 
patients without kidney injury while plasma creatinine did not change. Serum 
cystatin C was not beneficial in detection of AKI. Urine N-acetyl-β-D-
glucosaminidase increased with all the heart transplant patients after 
cardiopulmonary bypass, and it was not able to identify patients with clinical 
kidney injury.  
 
3. Prophylactic treatment with intravenously administrated N-acetylcysteine has no 
renoprotective effects in patients with minor kidney injury undergoing cardiac 
surgery. 
 
4. Perioperatively administrated levosimendan has not significant effects on renal 
functions of coronary artery bypass patients with compromised left ventricle 
function. 
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